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Abstract 
HIV-1 Elimination in Humanized Mice 
Hang Su, Ph.D. 
University of Nebraska Medical Center, 2019 
Supervisor: Howard E. Gendelman, M.D. 
Human immunodeficiency virus type one (HIV-1) exclusively infects humans and 
chimpanzees. Therefore, animal models are required for all investigations of viral 
pathogenesis, therapy and cure. Immunodeficient mice transplanted with human 
hematopoietic stem cells, termed humanized mice, support the development of multiple 
human cell lineages throughout the cell’s life span. To this end, we used humanized mice 
to evaluate the dynamic changes of host immunologic and viral profiles during both acute 
and chronic HIV-1 infection. We identified the temporal and spatial distribution of HIV-1 
cell and tissue compartment infections and outlined correlations made between viral 
progression and host immunity by comparing two different humanized mouse models. 
Based on the discovery of early viral set-points, we developed a paradigm for a potential 
‘HIV-1 cure’ by sequential administration of long-acting slow-effective release 
antiretroviral therapy (LASER ART) and CRISPR-Cas9 treatments. HIV-1 elimination 
was achieved in a third of dual-treated humanized mice after exhaustive works to detect 
HIV-1 and its gene products in peripheral blood, brain, lung, liver, spleen, kidney, gut, and 
bone marrow (BM). This was done by sensitive nested and digital-droplet PCR and 
RNAscope tests. Immune function was preserved in animals where HIV-1 was eliminated. 
In vivo viral outgrowth assay (VOA) was employed to confirm HIV-1 elimination by 
adoptive transfer of donor splenocytes and BM cells into naïve humanized mice. While 
 v 
virus was successfully recovered from HIV-1 control, LASER ART or CRISPR-Cas9 
alone treated animals virus could not be recovered in recipients transplanted from a third 
of the dual-treated “cured” animals. We further characterized the impact of humanized 
mice-based VOA in viral isolation assay by expanding the sample sizes. We observed that 
replication-competent HIV-1 persisted in multiple tissues even when plasma viral load was 
undetectable and virus can be readily recovered from naïve humanized mice. We 
demonstrate that in vivo VOA using humanized mice is a sensitive assay system to 
interrogate replication competent HIV-1 and can be employed to determine viral 
eradication from donor samples. To this end, we used the humanized mouse model to study 
HIV-1 tissue compartmentalization, interrogate HIV-1 eradication employing innovative 
technologies, and assess HIV-1 elimination using humanized mice-based VOA, which will 
facilitate future translational studies.  
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Chapter 1 Introduction 
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1.1 HIV-1 reservoirs 
The wide spread use of antiretroviral therapy (ART) has heralded a remarkable 
milestone for the treatment of human immunodeficiency virus type one (HIV-1) infection. 
Disease morbidity and mortalities have been reduced significantly and infection is now 
medically manageable with viremia suppressed to undetectable levels. Also, there is 
preservation of CD4+ T cell and global immune function (1-3). This includes, but is not 
limited to, the maintenance of fully functional circulating and tissue CD4+ T cells (4, 5). 
However, ART requires life-long uninterrupted treatments. This is as a consequence of 
HIV-1 persistence as latent replication-competent genomic integrated provirus. Such HIV-
1 infected cells persist with an average half-life of 44 months. This occurs with or without 
suppressive ART. It is estimated to take up to 70 years for complete viral decay (6). 
Underlying the need for continuous ART is the speed of viral rebound that typically ensues 
within 2 weeks after antiretroviral drug (ARV) discontinuation (7-9). Therefore, viral 
reservoirs are the major obstacle towards securing an HIV-1 cure. 
HIV-1 reservoirs are a pool of infected cells containing replication-competent viral 
sequence whereas extremely low or no viral antigens are expressed. HIV-1 reservoirs are 
distributed in human body across a broad range of cell (principally CD4+ T cells) and tissue 
(gut-associated lymphoid tissue (GALT), spleen, lymph nodes, brain, genitourinary system 
and lung, see below) (Figure 1.1). The best characterized HIV-1 reservoir is resting CD4+ 
T cells, of which most are present with a memory phenotype. Memory T cells can be further 
allocated to stem cell memory (TSCM), central memory (TCM), transitional memory 
(TTM), effector memory (TEM), migratory memory (TMM), tissue resident memory 
(TRM) and terminally differentiated (TTD) cells (10, 11). While individual memory T cell  
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type contributes to HIV-1 reservoirs to different degrees, TCM is considered as a major  
source of viral latency (10, 11). Monocyte-macrophages also play a prominent role in HIV-
1 latency that viral DNA/RNA and antigens can be detected in patients after long-term 
effective ART (12, 13). Macrophages are long-lived and resistant to cytotoxic T 
lymphocytes-mediated killing which make them ideal candidates as HIV-1 reservoirs (14). 
Other cell types such as dendritic cells, epithelial cells, and hematopoietic stem/precursor 
cells may also serve as HIV-1 reservoirs that need further investigation (10, 15). 
Tissues represent major HIV-1 sanctuaries where tremendous amounts of viral 
susceptible immune cells reside along with limited ART penetration (16). While peripheral 
CD4+ T lymphocytes are easy to access in the clinic and have been extensively interrogated 
as the surrogate of HIV-1 reservoirs, it is noteworthy that more than 98% of total body 
CD4+ T lymphocytes reside throughout variant tissues (17). Tissue-derived macrophages 
have also been reported to harbor latent HIV-1 (18, 19). GALT and lymph nodes, which 
are the most accessible tissue samples in the clinic, have been employed as surrogates to 
determine HIV-1 tissue infection in patients. GALT is one of the earliest breached organs 
during acute HIV-1 infection. Studies have discovered active viral replication and 
depletion of memory CD4+ T cell during early HIV/SIV infection (20). Persistence of viral 
DNA/RNA was observed in GALT even after years of effective ART (21, 22). Early viral 
invasion of lymph nodes has been reported in humans (23). Lymph nodes are characterized 
as diverse viral susceptible immune cells, lower ART concentrations, and resistance to 
cytotoxic CD8+ T cells and NK cells surveillance. Altogether lymph nodes are an ideal 
sanctuary maintaining HIV-1 replication under treatment (24). Recently the follicular 
dendritic cell (FDC) network that locates in the lymphoid tissues has drawn attention as an 
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HIV-1 shelter. The FDC system traps viral particles that facilitates infection of massive 
immune cells that are located, especially follicular CD4+ helper T cells (TFH) and 
follicular regulatory T cells (TFR) which support active HIV-1 infection and maintain 
HIV-1 latency during ART (25, 26). This emphasizes the significance of lymphoid tissues 
such as GALT, lymph nodes, and spleen as HIV-1 tissue reservoirs. Compared to the other 
two, spleen viral infection is much under studied due to difficulty of sample access. Using 
simian immunodeficiency virus-infected macaque model spleen is identified as an active 
viral infection site as well as viral sanctuary during ART (27). Lung and liver contain 
plentiful HIV-1 susceptible cells, especially myeloid-derived macrophages (alveolar 
macrophages and Kupffer cells). Although there is evidence showing that both tissues 
harbor HIV-1 in untreated patients (28, 29), their contribution to systemic viral persistence 
under highly suppressive ART is unclear. Studies have found that viral 
compartmentalization existed between lung, liver and peripheral blood (29, 30). In addition, 
viral particles were successfully recovered from tissue-specific macrophages in patients 
with controlled viremia (31), suggesting that myeloid cells may represent the major HIV-
1 reservoirs in these two organs. The long-lived hematopoietic progenitor cells (HPCs) 
located in bone marrow hold the potential of self-renewal and differentiation to different 
cellular lineages that can serve as HIV-1 reservoirs as soon as they start to express major 
HIV-1 receptor CD4 and co-receptors CCR5 and CXCR4 (32). Although it remains unclear 
if hematopoietic stem cells maintain HIV-1 latency, persistent viral infection was observed 
in both untreated and ART-treated bone marrow cells (32, 33). HIV-1 is also tracked in 
other tissue types such as kidney where multiple cell types were found susceptible to viral 
infection (34). However, the contribution of various anatomical sites to HIV-1 latency 
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needs further investigation. Lamers el al. scrutinized 229 autopsy samples from 20 HIV-1 
patients who received ART and exhibited low or undetectable plasma viral load (VL) and 
cerebrospinal fluid (CSF) prior to death. A wide spectrum of tissue types was covered 
including brain, aorta, colon, kidney, liver, lung, lymph nodes, spleen, and testis. 
Surprisingly, although HIV-1 tissue distribution varies between patients, viral DNA was 
recovered from all the participants (35). This report confirmed that HIV-1 persists in tissues 
under long-term effective ART even when plasma VL is undetected. Development of 
strategies that can target and eliminate tissue HIV-1 infection is critical to achieve HIV-1 
cure. 
1.2 Animal models for studies of HIV-1 pathogenesis 
HIV-1 is a species-specific pathogen that only infects humans and chimpanzees 
(36-38). Therefore, a major obstacle in investigating the pathophysiology and assessing 
novel treatment of HIV-1 and AIDS rests on the development of animal models that readily 
reflect virus-to-host interactions as in human. HIV-1 originates from its counterpart simian 
immunodeficiency virus (SIV) that infects non-human primates (NHPs) symptomatically 
or asymptomatically depending on viral strains and host species (39). Therefore, SIV-
infected macaques including three most commonly used species, rhesus macaques 
(Macaca mulatta), pigtailed macaques (Macaca nemestrina), and cynomolgus macaques 
(Macaca fascicularis), have become valuable tools to study HIV-1 infection. Indeed, with 
a similar immune system, NHP models have successfully recapitulated major symptoms of 
HIV-1 infection in human including CD4+ T cell depletion, peripheral and tissue viral 
replication, viral control under functional CD8+ T cell and ART administration, 
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establishment and reversal of viral latency, and development of AIDS (40). Additionally, 
NHPs provide more accessible tissue sample acquisition, controlled experimental design 
(infection, treatment, and treatment interruption), and tests of novel regimens and 
techniques not easily done in humans. NHP models have extended our understanding of 
HIV/AIDS pathobiology and facilitated our progress on HIV-1 cure. However, it is 
noteworthy that SIV and HIV are still genetically different viruses with only 53% sequence 
identity (41). This reflects on the different compositions of human leukocyte antigen (HLA) 
genes between HIV and SIV that account for viral antigen recognition and cellular 
restriction factors such as tripartite motif-5alpha isoform (TRIM5α) and apolipoprotein 
beta mRNA-editing enzyme catabolic polypeptide 1-like protein G (APOBEC3G) that 
affect viral entry into cells (39). Altogether, these factors lead to more rapid disease 
progression in SIV-infected rhesus macaque than in HIV-infected human. It may also 
explain many failures during reproduction of SIV discoveries in HIV. In addition, high cost 
of NHPs significantly impedes the usage of this model in large scalable studies that require 
assessment of multiple experimental parameters. Therefore, small murine models, namely 
humanized mice, have been developed to compensate these limitations.  
The principle of generating humanized mice is to reconstitute human CD34+ 
hematopoietic stem cells (HSCs) that are isolated from fetal livers or umbilical cord blood 
into murine with immunodeficient background such as NSG (NOD.Cg-
PrkdcscidIL2rgtm1Wjll/Sz), NOG (NOD.Cg-PrkdcscidIl2rgtm1Sug), and NRG (NOD-
Rag1tm1MomIL2rgtm1Wjll/Sz) (42). Multiple lineages of human immune cells including T 
cells, B cells, NK cells, monocytes/macrophages, and dendritic cells can be established and 
sustained in mouse peripheral blood as well as various tissues including brain, lung, spleen, 
 7 
kidney, liver, gut, and bone marrow (BM). To this end, these humanized mice can be used 
as a platform to support human disease studies (e.g. HIV-1). For relative low expense and 
short lifespan (about 1 year) of animals, humanized mice are more accessible, easier to 
scale up, and can be employed for reasonable long periods of studies. 
Using HIV-1 infected human CD34+ HSCs-reconstituted NSG (hu-HSC) mice, our 
lab observed a sustained CD4+ T cell decrease in both peripheral blood and tissues (spleen 
and BM) as detected in clinical patients (43). Multiple forms of HIV-1 DNA and RNA was 
identified in a broad spectrum of tissues including BM, spleen, lung, gut, brain, kidney, 
and liver. We further analyzed dynamic changes of numbers and distributions of cell 
subtypes including CD34+ progenitor cells, monocyte-macrophages, dendritic cells, 
regulatory CD4+ T cells, and memory T cells (stem cell memory, naïve memory, central 
memory, and effector memory) and identified HIV-1 infection in each individual cell types. 
Our discoveries using humanized mice either paralleled with what has been observed in 
HIV-1 infected patients or provided new insights of HIV-1 pathophysiology. Together it 
demonstrated that humanized mouse models are valid platforms that recapture the 
characteristics of HIV-1 infection. We further employed humanized mice to evaluate the 
pharmacokinetic (PK) and pharmacodynamic (PD) profiles of parent ART and house-made 
modified ART (a HIV-1 integrase inhibitor dolutegravir (DTG) in this case). In the initial 
screen, a single dose of intramuscular (IM) injection of native DTG or prodrug DTG 
(nanoformulated myristyl (NMDTG) in this case) was administered to human peripheral 
blood lymphocytes (hu-PBLs)-reconstituted NSG mice. Animals were infected at either 2 
or 4 weeks after treatment and kept for another 10 days before sacrifice. NMDTG exhibited 
superior PK and PD profiles over native DTG as shown by sustained higher levels of parent 
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drug in both peripheral blood and multiple tissues (spleen, gut, liver, lung, and kidney) and 
lower HIV-1 expression was observed in NMDTG-treated animals compared to native 
DTG-treated animals. Similar results were confirmed when NMDTG was tested using hu-
HSC mice (44). In addition, the characteristics of other drugs, e.g. nanoformulated 
cabotegravir (CAB), were also successfully assessed using humanize mouse model (45). 
Together, humanized mice have been demonstrated as a valid laboratory tool to investigate 
preclinical virology, immunology, pathogenesis, therapy, and potential eradication of HIV-
1. 
1.3 Strategies for HIV-1 cure 
ART has led to considerable success on maintaining HIV-1 suppression and 
relatively normal immune function which combines to render a nearly normal life 
expectancy in patients. However, ART does not eradicate HIV-1 reservoirs that drive viral 
rebound upon ART discontinuation. In addition, cells that are considered HIV-1 reservoirs 
are usually long lived such as memory CD4+ T cells which withhold a half- life up to 4 
years. At this rate, it will take 73 years to naturally eradicate a reservoir size of 106 cells 
(46). As a result, ART requires life-long adherence that renders the patients of treatment-
associated side effects and toxicities along with high expenses and stigma associated with 
the disease. To this end, an HIV-1 cure is highly urged in the community. To date, there 
have been only 2 cases of HIV-1 cure, the “Berlin patient” and the “London patient” who 
underwent similar procedures (47, 48). Both patients received allogeneic hematopoietic 
stem cell transplantation (HSCT) from the respective donor with a homozygous mutation 
in the HIV coreceptor CCR5 (CCR5Δ32/Δ32) for the treatment of tumorous malignancy. 
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Both patients underwent ART interruption later after the procedures and have remained 
viral remission for 10 and 2 years, respectively (47, 48). While the news remains exciting, 
it is unrealistic to put millions of HIV-1 patients into aggressive chemotherapy/irradiation 
and highly risky HSCT. Indeed, at least 6 other cancer patients who went through similar 
procedures died within 12 months after transplantation due to cancer relapse, graft versus 
host disease (GvHD), or other comorbidities (49). Nevertheless, these two cases 
demonstrated that HIV-1 cure can be realized when viral reservoirs are completely 
eliminated (the so-called “sterilizing cure”) that is assumed to have happened to both 
patients. What can be implied is that a smaller HIV-1 reservoir size may lead to delayed 
viral rebound and even long-term viral remission in the absence of ART, namely functional 
cure. This was demonstrated in the “Mississippi child” case who acquired perinatal HIV-1 
infection and started ART at 30 hours after birth. Treatment was discontinued by the 
parents at age of 18 months and a delayed viral rebound until 27 months later was achieved, 
indicating limited amounts of HIV-1 reservoirs achieved by early ART administration may 
set up a foundation for long-term viral control (50). Reduction of HIV-1 latency burden 
was also observed in early treated adults (51). In this study, HIV-1 latency was found to be 
established within 2 weeks of infection. However, compared to untreated patients, 
individuals who started ART at early stage had much lower levels of total and integrated 
HIV-1 DNA that represented a smaller size of HIV-1 latency. In addition, lower viral 
reservoir level is correlated to prolonged viral remission (52). In the VISCONTI cohort, 
patients, termed posttreatment controllers (PTCs), initiated ART during acute HIV-1 
infection and maintained viral suppression for several years upon treatment interruption 
(53). It is noteworthy that early ART alone does not eliminate HIV-1 infection. In a recent 
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report, patients that initiated ART during Fiebig I stage (positive HIV-1 RNA, negative 
HIV-1 antigen/antibody) (54) that is considered the earliest stage of infection all 
experienced rapid viral rebound following treatment interruption (55). The median rebound 
time was 26 days which is no different from general populations that undergo ART 
intervention (56, 57). Even so, early ART successfully prevents HIV-1 transmission, limits 
viral escape, improves immune function, and reduce HIV-1 associated morbidity and 
mortality in the long run. Therefore, early treatment set the foundation for HIV-1 cure 
which might be achieved when other strategies are combined.  
HIV-1 reservoirs remain latent in ART-treated individuals with minimal to no viral 
transcription/translation, needed to evade immune surveillance and ART responses (58). 
To expose the footprint of reservoirs, an approach termed “shock and kill” was developed 
that implements latency-reversing agents (LRAs) to reawaken dormant virus (shock) from 
latently-infected cells and induces viral and/or immune-mediated cell death (kill), while 
sustained ART prevents newly produced virus from infecting healthy cells (59). HIV-1 
latency is maintained through several mechanisms including HIV-1 integration site and 
orientation, DNA methylation and histone deacetylation, lack of key transcription factors, 
inhibition of transcriptional elongation, and others (60). To target each mechanism, 
respective reagents were developed including histone methyltransferase inhibitors (HMTi), 
histone deacetylase inhibitors (HDACi), protein kinase C (PKC) agonists, positive 
transcription elongation factor b (P-TEFb) activators, and disulfiram. Because many of 
these compounds are developed and already implemented in cancer and other medical field, 
researchers were able to accelerate their clinic tests on antiviral functions after in vitro and 
ex vivo evaluations. Currently, there are over 160 chemicals identified as LRAs that have 
 11 
been tested preclinically or clinically in small scale (59, 61-63). To date, while certain 
LRAs are able to induce cell-associated HIV-1 RNA transcription and/or plasma HIV-1 
RNA production, no reductions in HIV-1 reservoirs or delay in viral rebound have been 
met. Major concerns and suggested improvements have been proposed (59, 62, 64). First, 
the mechanisms by which present LRAs may affect infected and uninfected cells would 
cause generalized disturbance of homeostasis. Therefore, the dose, quantity, and frequency 
of LRAs needs cautious consideration and inevitably compromises their latency-reversing 
function (65). New generations of small molecules such as second mitochondrial activator 
of caspases mimetic (SMACm) acting on alternative pathways have exhibited partial 
immune activation while preserving efficacy for HIV-1 reactivation (59). Also, some of 
these compounds synergized with current LRAs on viral reactivation and remain front 
runners for clinical trials. It is noteworthy that these newly developed molecules are not 
viral unique emphasizing the continuous demand of more specific LRAs with high potency 
and minimal side effects. HIV-1 reservoirs distinguish themselves from healthy cells 
through their apoptosis-resistant characteristics (63). Cummins et al. demonstrated that co-
treatment with a major apoptotic inhibitor, the B cell lymphoma 2 (Bcl-2) antagonist 
venetoclax, in αCD3/αCD28-treated cells from virally suppressed patients could induce 
preferential killing of HIV-1 infected cells, with minimal death of uninfected cells. More 
importantly, cell-associated viral DNA was significantly reduced upon dual-treatment 
compared to αCD3/αCD28 treatment alone (66). This virus-specific elimination strategy, 
named “prime, shock, and kill”, needs further in vivo evaluation. Lack of efficacy is another 
shortcoming of current LRAs that reflects on both short half-lives and reactivation 
incompetency. Stochastic reactivation of HIV-1 latency requires repeated stimulation to 
 12 
shrink reservoir size (67) and the activation effect is likely correlated to LRA 
concentrations (65). These, in combination, demand a high dose frequency and volume of 
LRAs leading to potential toxicity (59).  
Nanotechnology offers a solution by formulating regimens into nanosuspensions 
that can prolong drug half-lives and reduce dosing frequencies (68, 69). In both preclinical 
and clinical studies, nanoformulated long acting ART has shown superior drug retention, 
release, and tissue penetration with minimal side effects when compared to native ART 
(70-73). Nanoformulation of LRAs is much under developed. Buehler et al. engineered 
self-assembling vault nanoparticles containing bryostatin-1 that exhibited HIV-1 
reactivation and cell activation function using J-Lat cell line as latency model (74). 
Kovochich et al. showed that lipid nanoparticle-encapsulated bryostatin-2 enhanced HIV-
1 latency reversal from J-Lat cells compared to conventional regimens (75). Notably, co-
delivery of ART and LRA by nanoparticles, simultaneously reversed HIV-1 latency and 
prevented viral spread (75, 76). Further interrogation of such a co-delivery system towards 
reducing HIV-1 reservoirs should be pursued. Although there is still a long way to go 
before the realization of clinical use of nanoformulation on HIV-1 treatment, it is an 
appealing direction in terms of easing patients’ life, improving clinical adherence, and 
lowering potential drug toxicity and side effects. Heterogeneity of HIV-1 reservoirs makes 
it unlikely for a single LRA to act on all hidden targets. Indeed, a given LRA exhibited 
high variability on viral reactivation using different primary and patients’ cell samples 
while a specific cell model also reacts diversely upon distinct LRAs (77, 78). To overcome 
this hurdle, LRA combinations with variant mechanisms can be implemented that has 
shown enhanced viral reactivation compared to individual LRA alone in vitro and ex vivo 
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(79, 80). In addition, by using drug combinations, single drug dose can be reduced. Co-
formulation and co-delivery systems through nanocarriers could also be developed to 
simplify treatments.  
Another concern for unsuccessful “shock and kill” is suboptimal “killing” of 
latently infected cells (80). Competent CTLs are prominent in HIV-1 surveillance as 
observed in initial viral control during acute infection, greater potency in elite controller 
that are able to naturally maintain viral suppression without taking cART, and rapid 
viremia rebound in SIV-infected macaques upon CD8+ T cell depletion (81). Nevertheless, 
during chronic infection, CTLs then become functionally exhausted featuring increased 
expression of immune checkpoint markers such as programmed cell death protein 1 (PD1), 
cytotoxic T lymphocyte antigen 4 (CTLA4), T cell immunoglobulin mucin receptor 3 
(TIM3), and lymphocyte activation gene 3 protein (LAG3). PD1 is one of the best 
characterized immune checkpoint molecules. Under physiological conditions, upon T cell 
activation PD1 expression is increased to avoid excessive immune stimulation for 
maintaining biological homeostasis. Nevertheless, overexpression of PD1 causes immune 
‘exhaustion’ that impairs effector function and leads the organisms less defensive against 
diseases (82). PD1 ligand (PDL1) expression is broadly upregulated in several cancer types 
to escape immune control (83) whereas the inhibition of PD1/PDL1 pathway restores T 
cell function and mitigates tumor progress (84). Since T cells are the major targets of HIV 
and also undertake direct antiviral responses, it is not surprising to observe an upregulation 
of PD1 on both CD4+ and CD8+ T cells in untreated HIV patients (85, 86). However, upon 
ART, PD1 expression is reduced on CD4+ and CD8+ T cells, demonstrating that sustained 
antigen exposure is pivotal for PD1 expression and immune exhaustion (87). In SIV 
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infected rhesus macaques, the blockade of PD1 using anti-PD1 antibody resulted in the 
expansion of HIV specific CD8+ T cells presenting enhanced antiviral function, leading to 
decreased plasma viral load as well as prolonged animal survival (88). In addition, a recent 
report demonstrated that PD1 blockade synergized with ART by improving CD8+ T cell 
proliferation, restoring CD8+ T cell function, and enhancing viral suppression in SIV 
infected macaques. By far, there is only one clinical study applying anti-PDL1 antibody on 
treated HIV infected patients without malignancy in which increased HIV-specific CD4+ 
and CD8+ T cells were observed after antibody infusion (89). PD1/PDL1 molecules also 
contribute to HIV latency. A positive correlation was identified between the frequency of 
PD1+ cells and the size of HIV reservoirs (90). Within memory CD4+ T cells from ART 
treated patients, HIV DNA was enriched in PD1 high compared to PD1 low expressing 
cells, indicating PD1 level may play a major role in maintaining HIV persistence (91). 
Blockade of PD1 was suggested to destabilize the HIV reservoirs whereas whether or not 
PD1 inhibition can affect reservoir size and potential viral cure needs further investigation. 
Broadly neutralizing antibodies (bNAbs) is another potent tool for clearance of free HIV-
1 or infected cells through binding of Fc region and subsequent cellular phagocytosis and 
antibody-dependent cellular cytotoxicity (ADCC) (92). In HIV-1 infected untreated 
patients, bNAbs have demonstrated capacity to reduce plasma viremia (93, 94). However, 
when bNAbs were administered to viral suppressed patients, no change of peripheral CD4+ 
T cells total and integrated HIV-1 DNA was observed (94). This could be due to a lack of 
viral expression in HIV-1 reservoirs that are required for bNAbs to recognize in order to 
clear. Therefore, it is rational to combine LRAs and bNAbs in an attempt to limit HIV-1 
reservoirs. To this end, Borducchi et al. employed a combination of GS-9620 (a toll-like 
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receptor 7 (TLR7) agonist) and bNAb PGT121 in acute simian-human immunodeficiency 
virus (SHIV)-infected macaques during ART and plasma VL was monitored for 196 days 
after treatment interruption. While viral rebound was observed in 11/11, 10/11, and 9/11 
of positive controls, GS-9620, and PGT121 single treated animals, respectively, only 6/11 
animals rebounded from dual-treated group (95). How this combinational strategy will 
affect HIV-1 latency in human is under active pursuit (NCT02850016 and NCT03041012).  
While efforts devoted to developing new LRAs and combinational strategies 
continue, alternative timing of LRA administration is worth investigation. As mentioned 
above, although ART initiation during early HIV-1 infection successfully reduces reservoir 
size it alone does lead to viral elimination. Studies also showed that viral sequences from 
remained reservoirs and relapse are highly similar to that isolated shortly before ART 
started (55, 96, 97). This indicates that although early ART does not prevent latency 
formation it successfully halts viral evolution that eases designs for further latency 
targeting. The question that remains lies on how to maximally diminish the setup reservoir 
pool as ART is initiated. Although HIV-1 latency is established rapidly upon infection, it 
is relatively unstable as shown by quick turnover of viral DNA before treatment initiates 
(98). This is likely due to a pro-inflammatory environment along with highly expressed 
viral antigen that favors T-cell activation and hinders the formation of HIV-1 latency. One 
can speculate that adding LRA to ART during early HIV-1 infection may further restrain 
viral reservoir size compared to ART alone (99, 100). Notably, “earlier” ART intervention 
may not necessarily be “better” for developing effective antiretroviral immune responses 
(101). Such early intervention blunts the generation of HIV-1 specific CTLs that may 
explain the failure of viral control upon ART interruption in early treated patients (55). To 
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overcome this challenge, immune enhancers such as bNAbs , therapeutic vaccine, and 
chimeric antigen receptor T cells (CAR-T) can be adopted to induce cytotoxic T cell 
responses as mentioned above (95). To be noted, although ART was started early at 7 days 
post-infection in this study, GS-9620 and PGT121 were administered during chronic 
infection when viral reservoirs are relatively stable. A higher rate of viral remission might 
be achievable if both reagents were applied during early infection when viral latency was 
not readily established. To this end, it holds promise that an early interfering cocktail 
containing LRA, immunotherapy, and ART can maximize latency restriction, if not 
complete eradication and can optimally filter reservoir populations with limited diversity 
for subsequent selective destruction, e.g. gene therapy as discussed below. 
Gene editing technology deploys various biological enzymes such as zinc finger 
nucleases (ZFN), transcription activator-like effector nucleases (TALEN), and clustered 
regularly interspaced short palindromic repeats (CRISPR), to modify the host genome in 
the manners of gene  regulation, gene knock-in and knock-out, and epigenetic modulation 
(102). Current ART targets HIV-1 transcription and translation levels but does not affect 
viral sequences that integrate into the host genome. Nevertheless, complete HIV-1 
eradication requires clearance of each individual virus that likely happened in the “Berlin 
patient” and “London patient”. Therefore, gene editing could be the final solution to 
achieve an HIV-1 cure. Following the success of the first ever HIV-1 cure through HSCT 
of CCR5 mutated cells, the field was highly interested in the modification of CCR5 
expression from patients’ autologous T cells. In a phase 1 study, CD4+ T cells isolated 
from HIV-1 suppressed patients were engineered to delete CCR5 expression using ZFN ex 
vivo and infused back to patients (103). The primary goal of the study was achieved which 
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proved the capability and safety of gene editing of human cells. Even though during ART 
interruption, all the patients experienced HIV-1 rebound, CCR5-modified CD4+ T cells 
exhibited resistance to viral infection and sustained in both peripheral blood and mucosal 
tissues with a mean half-life of 48 weeks. CCR5 modification on hematopoietic 
stem/progenitor cells (HSPCs) was also realized using ZFN or CRISPR/Cas9 technology 
that subsequently differentiated into multilineages of human cells resistant to HIV-1 
infection. Primary studies using humanized mouse models demonstrated that animals 
engrafted with CCR5-modified cells presented better CD4+ T cell reservation and lower 
HIV-1 amplification compared to animals engrafted with CCR5-unmodified cells (104, 
105). The development of CRISPR/Cas9 system eases the design and improves the 
specificity and efficiency of gene editing. CRISPR/Cas9 is composed of two working 
machineries that the guide RNA (gRNA) is designed to complement specific target 
sequence while the Cas9 enzyme excises the respective sequence (106). To enhance 
excision efficiency, multiple gRNA targeting different portions of the aiming sequence can 
be deployed. Indeed, HIV-1 excision from host genome by CRISPR/Cas9 has been 
demonstrated in in vitro, ex vivo, and small animal models (107, 108). While so far none 
of the techniques alone is able to eliminate HIV-1 infection, gene therapy could add the 
final punch to the residual viral reservoirs when the majority has already been cleared. 
Based on this hypothesis, we conducted a proof-of-concept study using a combinational 
strategy through sequential treatment of ART in the form of long acting slow effective 
release ART (LASER ART) and CRISPR/Cas9 targeting of the LTR-Gag region to 
infected humanized mice (109). For the first time, we achieved a complete elimination of 
HIV-1 in a subset of infected humanized mice, as demonstrated by the absence of viral 
 18 
DNA/RNA from both peripheral blood and multiple tissue compartments along with failure 
of viral recovery using both in vitro and in vivo viral outgrowth assays (VOAs). This study 
provides the possibility of achieving HIV-1 cure through combinatorial treatments 
containing gene editing.  
Challenges to achieve complete HIV-1 elimination remain. Different combination 
strategies should be exercised to optimize for a 100% cure rate. Off-target effects, side 
effects, and potential toxicities of each individual therapy and drug-drug interaction should 
be cautiously evaluated before moving into humans. While multiple arms targeting HIV-1 
elimination are advancing rapidly including pharmacological approaches, immune 
boosting, and genome editing, HIV-1 cure is no longer a fantasy but an achievable goal.   
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Chapter 2 Immune Activations and Viral Tissue Compartmentalization 




Human immunodeficiency virus type one (HIV-1) tissue compartments are 
established soon after viral infection. However, the timing in which virus gains a permanent 
foothold in tissue and the cellular factors that control early viral-immune events are 
incompletely understood. These are critical events in studies of HIV-1 pathogenesis and in 
the development of viral reservoirs after antiretroviral therapy. Moreover, factors affecting 
the permanence of viral-tissue interactions underlie barriers designed to eliminate HIV-1 
infection. To this end we investigated the temporal and spatial viral and host factors during 
HIV-1 seeding of tissue compartments. Two humanized NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ 
mouse models were employed. In the first, immune deficient mice were reconstituted with 
human CD34+ cord blood hematopoietic stem cells (HSC) (hu-HSC) and in the second 
mice were transplanted with adult mature human peripheral lymphocytes (hu-PBL). Both, 
in measure, reflect relationships between immune activation and viral infection as seen in 
an infected human host. Following humanization both mice models were infected with 
HIV-1ADA at 10
4 50% tissue culture infective doses. Viral nucleic acids and protein and 
immune cell profiles were assayed in brain, lung, spleen, liver, kidney, lymph nodes, bone 
marrow, and gut from 3 to 42 days. Peripheral CD4+ T cell loss began at 3 days together 
with detection of HIV-1 RNA in both mouse models after initiation of HIV-1 infection. 
HIV-1 was observed in all tested tissues at days 3 and 14 in hu- PBL and HSC mice, 
respectively. Immune impairment was most prominent in hu-PBL mice. T cell maturation 
and inflammation factors were linked directly to viral tissue seeding in both mouse models. 
We conclude that early viral tissue compartmentalization provides a roadmap for 
investigations into HIV-1 elimination. 
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2.2 Introduction 
Following the introduction of antiretroviral therapy (ART) in the mid-1990s, 
remarkable progress was made towards reducing disease morbidities and mortality during 
a life-long human immunodeficiency virus type one (HIV-1) infection (1-3). While ART 
efficiently controls viremia and preserves immune function (4) it does not eradicate 
infection (110). Recent discoveries suggested that HIV-1 persistence is established within 
two weeks of viral exposure (111). Thus, complete understanding of viral tissue 
compartmentalization needs be made in efforts to eliminate HIV-1 infection. 
To reflect the temporal and spatial challenges of human infection, animal models 
must reflect essential features of HIV-1 pathobiology in its human host (112). Insights into 
HIV-1 transmission and tissue distribution were made through studies of simian 
immunodeficiency virus (SIV) infection of nonhuman primates (113, 114). However, there 
are limitations in study. First, SIV and HIV are genetically and biologically distinct (41). 
Second, divergent viral and host factors affect progression to the acquired immune 
deficiency syndrome which commonly occurs more rapidly during SIV than HIV (41). 
Therefore, an HIV-1 susceptible animal model would be preferable for studies that reflect 
human infection. To such ends, humanized mouse models were developed. These models 
received engraftment of human cells into immunodeficient rodents resulting in the 
establishment of a functional human immune systems and tissue microenvironment that 
support long-term HIV-1 replication in target cells and tissues (115). Studies conducted by 
our group and others using such humanized mice have provided new insights into HIV-1 
virology, immunology, pathology, therapeutics, and modes of viral eradication (45, 71, 
116-118). However, to date, limited studies were performed to dissect when and to what 
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extent HIV-1 establishes persistent infection in tissue compartments. If this information is 
gleamed they could prove instrumental in developing improved antiretroviral therapies.  
In our prior works, chronic HIV-1 infected CD34+ hematopoietic stem cell (hu-
HSC) reconstituted NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were investigated (119-
121). They were used successfully to identify viral replication patterns and virus-induced 
injuries in diverse cell and tissue types. In the current study, attempts were made to better 
understand the temporal and spatial dynamics of viral seeding that followed HIV-1 
inoculation. To this end we tracked early viral footprints in tissue compartments. To 
compare how the host microenvironment could affect viral seeding we used both infected 
adult peripheral blood lymphocyte (hu-PBL) and hu-HSC mouse models. Animals were 
evaluated in parallel after infection and were necropsied at days 3, 5, 7, 14, 28, and 42. 
Results showed that peripheral CD4+ T cells decreased rapidly in infected hu-PBL mice 
with viral detection in all tissues within 3 days of infection. In contrast, in hu-HSC mice 
virus was detected in gut, kidney, spleen, lung, liver, and lymph nodes and in brain only 
by 14 and 28 days. HIV-1 nucleic acids and proteins demonstrated that the viral life cycle 
was completed in both humanized mice. Transcriptomic analysis demonstrated substantive 
immune activation and pro-inflammatory signature in hu-PBL compared to HSC mice that 
paralleled viral tissue compartmentalization. These data, taken together, demonstrate the 
dynamics and extent of HIV-1 tissue infections and its link to human immunity in relevant 
humanized mouse models of viral infection.  
2.3 Materials and Methods 
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2.3.1 Ethics Statement 
All animal studies were performed in compliance with UNMC institutional policies 
and the National Institutes of Health guidelines for laboratory animal housing and care, 
and were approved by the Institutional Animal Care and Use Committee of UNMC. Human 
monocytes were isolated by leukapheresis from HIV-1/2 and hepatitis seronegative donors 
exempt from UNMC Institutional Review Board (IRB) review. Human CD34+ 
hematopoietic stem cells were isolated from umbilical cord blood which is also exempt 
from UNMC IRB. 
2.3.2 Generation and HIV-1 infection of humanized mice 
NSG mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and 
housed under pathogen-free conditions in accordance with ethical guidelines for the care 
of laboratory animals at the National Institutes of Health and the University of Nebraska 
Medical Center. All experimental protocols were approved by the University of Nebraska 
Medical Center Institutional Animal Care and Use Committee (IACUC). 
To generate human CD34+ mice, the new born NSG mice were irradiated at a 1Gy 
by a RS 2000 biological irradiator (Rad Source Technologies Inc.), followed with 
intrahepatic engraftment of human CD34+ HSCs that were isolated from human cord blood. 
Humanization of the animals was monitored monthly from peripheral blood using flow 
cytometry analysis on human cell markers. At 20-22 weeks of age, a total of 31 animals 
with replicate levels of human cell reconstitution were selected then divided into uninfected 
(n=5) and HIV-1 infected mouse groups (n=26). The latter animals were infected 
intraperitoneally with HIV-1ADA at 10
4 TCID50 and then randomly distributed into groups 
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that were sacrificed at days 3 (n=5), 5 (n=5), 7 (n=5), 14 (n=5), 28 (n=3), and 42 (n=3) post 
viral challenge for further immune and viral analysis. 
Adult human PBL mice were generated by intraperitoneal injection of adult human 
peripheral blood lymphocytes purified from HIV-1 seronegative donor leukopaks into 8-
week old NSG mice at 25 × 106 PBLs/mouse. Ten days after engraftment, animal 
humanization was confirmed by flow cytometry. In total, 28 mice with replicate numbers 
of engrafted human cells were divided into uninfected (n=4) and HIV-1 infected groups 
(n=24) used for analyses. HIV-1ADA challenge was given intraperitoneally at 10
4 TCID50. 
Infected animals were then randomly distributed into groups that were sacrificed at days 3, 
5, 7 and 17 (n= 6, 5, 5 and 8) after viral infection for further immune and viral evaluations. 
2.3.3 Flow cytometry 
Peripheral blood was collected at designated time points into EDTA-coated tubes 
by cardiocentesis at the study end. Cellular phenotypes were analyzed for human 
antigens CD45, CD3, CD19, CD4, CD8, and CD14 (BD Pharmingen, San Diego, CA) 
using the fluorescence-activated cell sorting (FACS) system BD LSR2 (BD 
Immunocytometry Systems, Mountain View, CA) system. CD45+ human cells were gated 
from total lymphocytes. The percentages of CD4+ and CD8+ cells were obtained from the 
gate set for human CD3+ T cells. Results were analyzed using FlowJo software (BD 
Pharmingen, San Diego, CA). 
2.3.4 Viral load analyses 
Plasma samples were isolated from animal peripheral blood by centrifugation. 
Plasma HIV-1 RNA levels were measured using an automated COBAS Amplicor System 
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V2.0/Taqman-48 system (Roche Molecular Diagnostics, Basel, Switzerland) as per the 
manufacturer’s instructions. 
2.3.5 Nucleic acid extraction and quantification 
Animal tissues were homogenized using a Qiagen Tissue Lyser II followed with 
total nucleic acids (DNA and RNA) extraction with Qiagen All Prep DNA/RNA Mini 
Kit (QIAGEN). Serial dilutions of HIV-1 DNA from the ACH-2 cell line, which contains 
one integrated viral copy per cell, served as the standard control (122). Tissue HIV-1 
RNA was first reverse-transcribed to complementary DNA using a cDNA synthesis kit 
(Invitrogen, MA) (123). HIV-1 DNA and RNA were quantified by semi-nested real-time 
PCR as previously described (121). The first round of the PCR was performed on a 
conventional PCR machine (T100 Thermal Cycler, BioRad, CA). The products were 
subsequently applied to the second round real-time PCR using TaqMan fluorescent probes 
on an ABI Prism 7000 real-time PCR machine (Applied Biosystems, MA). The expression 
levels of tissue HIV-1 DNA and RNA were normalized to those for the human CD45 gene 
(Life Technology, CA). The sensitivity of our assay is around 10 copies.  
2.3.6 RNAscope 
RNAscope was performed on 5-µm thick paraffin-embedded spleen sections 
(Advanced Cell Diagnostics, Hayward, CA) according to the manufacturer’s instructions. 
Anti-sense HIV-1 Clade B probe designed for targeting 854–8291 base pairs of HIV-1 
sequence was used for viral detection. Positive signals were expressed as single or clusters 
of brown dots. Human peptidylprolyl isomerase B (PPIB) was applied as controls for 
human genome. All the images were captured for 40X magnification. 
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2.3.7 Immunohistochemistry 
Tissue samples were collected at the time of animal autopsy, fixed with 4% 
paraformaldehyde, and embedded in paraffin. Tissue sections of 5-um thickness were cut 
and immuno-stained with HLA-DR (clone CR3/43, 1:100, DAKO, Carpinteria, CA) and 
HIV-1 p24 (1:10, DAKO) antibodies. The DAKO EnVision polymer-based system was 
used for staining development, and all the sections were counterstained with Mayer’s 
hematoxylin (116). Images were obtained with a Nuance EX camera fixed to a Nikon 
Eclipse E800 microscope using Nuance software (Cambridge Research & Instrumentation, 
Woburn, MA). Human HLA-DR images were taken at 20× magnifications and HIV-1p24 
images were captured at 40× objective magnifications.  
2.3.8 Human mRNA analysis of immune responses 
Humanized mouse spleen was harvested at animal necropsy followed with total 
RNA isolation using an RNease Mini Kit (QIAGEN). Complementary DNA (cDNA) was 
generated using a cDNA synthesis kit (Invitrogen, MA) and subscribed to RT2 PCR arrays 
for T & B cell activation analysis (QIAGEN). Quantitative RT-PCR was performed on 
an Master cycler® ep realplex as per the manufacturer's instructions (Eppendorf) and 
analyzed using RT2 Profiler PCR Array web-based data analysis software, version 3.5 
(QIAGEN). Gene networks analysis was performed using Ingenuity Pathway Analysis 
(QIAGEN). 
2.3.9 Statistical analyses 
Data were analyzed using GraphPad Prism 7.0 software (La Jolla, CA). The 
Student's t test was used for two-group comparison. A value of p < 0.05 was considered 
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statistically significantly different. All results were presented as the means ± the standard 
error of the mean (SEM). Fisher’s Exact Test was used to validate the IPA data of spleen 
of each canonical pathway. 
2.4 Results 
2.4.1 Immune profiles in HIV-1 infected humanized mice 
NSG mice were irradiated at birth then were transplanted by intrahepatic injection 
with human CD34+ cord blood hematopoietic stem cells (hu-HSC) (116). Monthly whole 
blood flow cytometry showed that by 22 weeks mouse blood contained 30-60% human 
immunocytes. Following HIV-1ADA infection at 10
4 50% tissue culture infection dose 
(TCID50)/animal, assays for viral and immune profiles were performed in blood and tissues 
at days 0, 3, 5, 7, 14, 28, and 42. Replicates of 3 to 5 animals were tested at each of the 
time points before and after infection (at the time of sacrifice) (Figure 2.1A). 
Our flow cytometric gating strategy is illustrated in Figure 2.2A.  Prior to HIV-1 
infection, the percentages of human CD45+ cells in hu-HSC mouse blood ranged between 
30 to 60% (Figure 2.1B). A significant decline was seen by 42 days (10.9% ± 0.9), but not 
much decline was observed in the earlier time points (Figure 2.1B). Percentages of human 
cells stayed consistent between HIV-1 infected and mock infected controls in hu-HSC 
spleen and bone marrow that ranged from 45 to 55% (Figure 2.2B, C).  
Progressive loss of CD4+ T cells in blood was observed in infected hu-HSC mice. 
The mean decreases in CD4+ T cells were 4.7% ± 5.1, 10.2% ± 2.2, 14.0% ± 0.8, 11.9% ± 
1.6, 14.0% ± 2.9, and 18.8% ± 1.8, at days 3, 5, 7, 14, 28, and 42, respectively. In parallel, 
CD8+ T cell counts were increased by 4.6% ± 3.8, 9.7% ± 2.0, 10.6% ± 1.6, 9.1% ± 1.3,  
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Figure 2. 1 Human lymphocyte responses following HIV-1 infection of hu-HSC mice.  
(A) The illustrated experimental design for hu-HSC mice human cell reconstitution, HIV-1 
infection, and serial animal sacrifice performed at days 0, 3, 5, 7, 14, 28, and 42. Animal numbers 
are N = 5, 5, 5, 5, 5, 3, and 3 at each of the time points. (B) Peripheral blood CD45+, CD4+, and 
CD8+ cell counts before/mock infection (blue) and after HIV-1 infection (red) for each of the time 
points by flow cytometry tests. Data are expressed as mean ± SEM and considered *, **, *** 





Figure 2. 2 Human cells in spleen and bone marrow in infected hu-HSC mice.  
(A) The gating strategy for this study is shown. In brief, human cells (hCD45+) were gated from 
total lymphocytes and subsequently separated into human T and B (hCD3+ and hCD19+) 
lymphocytes. Human CD4+ and CD8+ T cells were gated from hCD3+ cell populations. (B) 
Splenocytes and (C) bone marrow cells were acquired from hu-HSC mice at serial time points 
(days 0, 3, 5, 7, 14, 28, and 42) after HIV-1 infection and subjected to flow cytometric analyses. 
Numbers of human CD45+, CD4+, and CD8+ cells in both tissues are expressed as mean ± SEM. 
Values were statistically significant if *p < 0.05. 
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3.8% ± 2.6, and 14.4% ± 1.1, at respective time points (Figure 2.1B). Splenocytes and 
bone marrow cells were collected at necropsy and showed parallel losses and increases in 
CD4+ and CD8+ T cells, respectively, in HIV-1 infected versus mock infected mice 
(Figure 2.2B-C).  
To compare virus-host interactions during early HIV-1 infection with 
immunologically “mature” hu-PBL mice, replicate evaluations were performed. Due to 
expected graft-versus-host disease in this model (124) testing was conducted up to 14 days. 
Adult NSG mice were engrafted with hu-PBL 10 days prior to HIV-1ADA infection with up 
to 8 animals/time point evaluated at days 0, 3, 5, 7, and 14 (Figure 2.3A). No significant 
changes of peripheral human CD45+ cell counts were observed in hu-PBL mice before and 
after infection. The values ranged from 25 to 45% of total immunocytes (Figure 2.3B). 
The depletion of CD4+ T cells was robust in infected hu-PBL mice. These equaled 24.1% 
± 4.6, 18.2% ± 3.0, 20.6% ± 2.6, and 37.4% ± 6.9, at days 3, 5, 7, and 14, respectively, 
following infection. In parallel, peripheral CD8+ T cell counts rose by 24.1% ± 4.3, 22.1% 
± 3.8, 21.3% ± 3.9, and 40.5% ± 7.6, at equivalent time points (Figure 2.3B). Taken 
together, the early and progressive impairment of human immune cells was observed 
during HIV-1 infection in both hu-HSC and hu-PBL mouse models, but more vigorously 
in hu-PBL than in hu-HSC mice. 
2.4.2 Plasma viral loads in HIV-1 infected humanized mice 
HIV-1 RNA appears before antiviral antibodies in blood at 10 to 14 days after viral 
exposure. To recapitulate these findings blood was collected from humanized mice and 
analyzed for viral loads by the COBAS Ampliprep V2.0 and Taqman-48 assay (Figure 
2.4). In hu-HSC mice, plasma HIV-1 RNA was detected in all animals with a mean of 5.0  
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± 3.4 x 104 copies/ml at 14 days after infection. At days 3, 5, and 7 after infection plasma 
viral loads were observed in 2/5 animals at or near to the detection limit of 400 copies/ml. 
Peak viremia was recorded at day 28 at a mean of 5.9 ± 3.4 x 105 copies/ml. At 42 days 
plasma viral load was at 6.6 ± 1.4 x 105 copies/ml (Figure 2.4A). 
In contrast, HIV-1 RNA was readily observed in all infected hu-PBL mice at day 3 
with the mean of 4.7 ± 0.8 x 103 copies/ml. A 2-log increase in viral copies were observed 
at days 5 and 7 with means of 5.4 ± 2.6 x 105 and 8.0 ± 3.5 x 107 copies/ml, respectively. 
At day 14, plasma viral load was 8.3 ± 4.8 x 107 copies/ml (Figure 2.4B). 
2.4.3 Tissue compartments in HIV-1 infected humanized mice  
HIV-1 infection is established in target tissues before viremia can be detected (125). 
To determine the early distribution of HIV-1 infection in tissues, gut, spleen, lung, liver, 
brain, and kidney were procured then evaluated after animal sacrifices (Figure 2.1A and 
2.3A). Tissue HIV-1 DNA and RNA were quantified by ultrasensitive semi-nested real-
time qPCR (121). In general, tissue viral levels were higher in longer infected hu-HSC and  
hu-PBL mice. In addition, tissue viral DNA and RNA corresponded to what was detected 
in plasma in both animal models (Figure 2.5A-B and 2.6A-B).   
In hu-HSC mice, HIV-1 DNA and RNA were detected at low levels within 3 days 
after viral challenge, from spleen, lung, and liver in 1/5 animals (Figure 2.5C-D). The 
same tissues examined at days 5 and 7 showed infection in 2/5 animals while HIV-1 
remained undetected in other tested tissues. In the animals infected for 14 days, viral DNA 
and RNA were observed in 3/5 gut, spleen, lung, and kidney tissues, and 2/5 liver samples 
(Figure 2.5C-D). However, HIV-1 was not detected in hu-HSC mouse brain until day 28. 




Figure 2. 3 Human lymphocyte responses following HIV-1 infection of hu-PBL mice.  
 
(A) The illustrated experimental design for hu-PBL mice human cell reconstitution, HIV-1 
infection, and serial animal sacrifice performed at days 0, 3, 5, 7, and 14. Animal number are N = 
4, 6, 5, 5, and 8 at each of the time points, respectively. (B) Peripheral blood CD45+, CD4+, and 
CD8+ cell counts before/mock infection (blue) and after HIV-1 infection (red) for each of the time 
points by flow cytometry tests. Data are expressed as mean ± SEM and considered **, *** 




Figure 2. 4 Peripheral viral loads during the course of HIV-1 infection.  
Plasma samples were collected following animal sacrifice from HIV-1 infected (A) hu-HSC and 
(B) hu-PBL mice. Fifty microliters of mouse sera were collected then diluted to 1 ml with sterile 
filtered healthy human sera enabling a detection limit (DL) of 400 HIV-1 RNA copies/ml that is 
illustrated by the dashed line. Each dot represents an individual animal. The mean HIV-1 copy 




Figure 2. 5 Viral tissue compartments in HIV-1 infected hu-HSC mice.  
Gut, spleen, lung, liver, brain, and kidney tissues were collected at necropsy at times indicated from 
HIV-1 infected hu-HSC mice, followed by assay of viral DNA and RNA by qPCR. The kinetics of 
(A) HIV-1 DNA and (B) HIV-1 RNA in each tissue are shown by colored straight lines assigning 
viral copies/106 hCD45+ cells (left Y axis) vs. time (X axis). The temporal relationship of viral 
load (acquired from Figure 2.4A) was plotted in red dashed line (right Y axis). Data are expressed 
as the means. (C) HIV-1 DNA and (D) HIV-1 RNA in tissues at single time point were listed with 
each dot representing an individual animal. Values below the horizontal line indicated that viral 




Figure 2. 5 Viral tissue compartments in HIV-1 infected hu-HSC mice.  
Gut, spleen, lung, liver, brain, and kidney tissues were collected at necropsy at times indicated from 
HIV-1 infected hu-HSC mice, followed by assay of viral DNA and RNA by qPCR. The kinetics of 
(A) HIV-1 DNA and (B) HIV-1 RNA in each tissue are shown by colored straight lines assigning 
viral copies/106 hCD45+ cells (left Y axis) vs. time (X axis). The temporal relationship of viral 
load (acquired from Figure 2.4A) was plotted in red dashed line (right Y axis). Data are expressed 
as the means. (C) HIV-1 DNA and (D) HIV-1 RNA in tissues at single time point were listed with 
each dot representing an individual animal. Values below the horizontal line indicated that viral 
DNA and RNA were below the DL. 
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Figure 2. 6 Viral tissue compartments in HIV-1 infected hu-PBL mice.  
Gut, spleen, lung, liver, brain, and kidney tissues were collected at necropsy at times indicated from 
HIV-1 infected hu-PBL mice, followed by assay of viral DNA and RNA by real-time qPCR. The 
kinetics of (A) HIV-1 DNA and (B) HIV-1 RNA in each tissue are shown by colored straight lines 
assigning viral copies/106 hCD45+ cells (left Y-axis) vs. time (X axis). The temporal relationship 
of viral load (acquired from Figure 2.4B) was plotted in red dashed line (right Y axis). Data are 
expressed as the means. (C) HIV-1 DNA and (D) HIV-1 RNA in tissues at single time point were 
listed with each dot representing an individual animal. Values below the horizontal line indicated 










Figure 2. 6 Viral tissue compartments in HIV-1 infected hu-PBL mice. 
Gut, spleen, lung, liver, brain, and kidney tissues were collected at necropsy at times indicated from 
HIV-1 infected hu-PBL mice, followed by assay of viral DNA and RNA by real-time qPCR. The 
kinetics of (A) HIV-1 DNA and (B) HIV-1 RNA in each tissue are shown by colored straight lines 
assigning viral copies/106 hCD45+ cells (left Y-axis) vs. time (X axis). The temporal relationship 
of viral load (acquired from Figure 2.4B) was plotted in red dashed line (right Y axis). Data are 
expressed as the means. (C) HIV-1 DNA and (D) HIV-1 RNA in tissues at single time point were 
listed with each dot representing an individual animal. Values below the horizontal line indicated 
that viral DNA and RNA were below the limit of detection.  
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animals (Figure 2.5C-D).  
HIV-1 was detected earlier and at higher levels in hu-PBL versus hu-HSC mouse 
tissues at all time points (Figure 2.6C-D). Viral DNA and RNA were seen by day 3 in 81% 
(29/36) gut, spleen, lung, liver, brain, and kidney tissues examined. At day 5, 93% (28/30) 
infected tissue were HIV nucleic acid positive. Notably, 67% (6/9) brain tissue samples 
from days 3 and 5 showed absent virus that supported later seeding for this tissue 
compartment. In the animals infected for 7 and 14 days virus was readily observed in all 
tissues (Figure 2.6C-D). HIV-1 DNA levels in gut were higher than that in all other tissues  
and supported the notion that gut serves as a prominent virus tissue compartment (Figure 
2.6A). Altogether, these data suggested that both peripheral and tissue HIV-1 
compartments were rapidly established in hu-HSC (day-14) and hu-PBL (day-3) mouse 
models, but much faster in hu-PBL than in hu-HSC mice. 
2.4.4 Confirmatory tests of viral gene expression in infected humanized mice 
To confirm tissue compartmentalization in early HIV-1 infected humanized mice, 
spleen sections were obtained then tested by RNAscope that can detect up to 1-2 copies of 
viral RNA (representative images shown in Figure 2.7). An antisense HIV-1 Clade B probe 
was employed which covers nearly entire viral genome (except LTR region). To this end, 
spleen HIV-1 RNA was shown as a single or cluster of brown dots, at the earliest stage of 
infection in both mouse models. In hu-HSC mice, HIV-1 RNA was visualized within 3 
days of infection, which reaffirmed the rapid set-up of viral tissue compartment. As 
infection proceeded, virus spread as shown in multiple clusters of brown dots within each 
tissue section. By day 42, viral burden was much more prominent with invaded cells 
aggregated throughout the observed field of interest (Figure 2.7A). In hu-PBL mice, HIV- 
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Figure 2. 7  Viral RNA tissue expression in infected humanized mice.  
 
Spleen tissues of hu-HSC (A) and hu-PBL (B) mice were collected with formalin fixed and paraffin 
embedded at necropsy. Five micrometer thick slices were prepared for RNAscope assays. 
Representative images from each group were shown with HIV-1 RNA labeled as single or cluster 
of brown dots. Images were taken at 40 x objective magnifications. 
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1 RNA was observed in all infected animal spleens at each time point. Viral RNA levels 
were comparable or higher in hu-PBL than hu-HSC mice at equivalent time courses 
(Figure 2.7B). 
2.4.5 Viral protein expression in infected humanized mice 
HIV-1p24 is a capsid component that is among the earliest expressed viral proteins. 
To assess its presence in infected tissues we employed immunohistochemistry assays to 
trace HIV-1p24 along with human HLA-DR staining. Representative photomicrographs 
were taken from each tissue sample stained with both antibodies (Figure 2.8). In hu-HSC 
mice, while HLA-DR+ cells were easily seen in the observation field, HIV-1p24 cells, 
however, were observed only in 1/5 animal spleens infected for 5 or 7 days. No infected 
cells were seen at 3 days. By day 14, 3/5 animals were HIV-1p24 positive. These 3 animals 
were the same ones where virus was detected by viral qPCR and RNAscope tests (Figure 
2.5 and 2.7). At 28 and 42 days, HIV-1p24 stained cells were demonstrated in all infected 
animals (Figure 2.8A). In hu-HSC lymph nodes, HIV-1p24 antigens were detected starting 
at 14 days after infection and increased over time (Figure 2.8A). 
In hu-PBL mice, HIV-1p24 antigens were captured in all infected animal spleens 
and lymph nodes during serial necropsies while human HLA-DR+ cells were well 
reconstituted (Figure 2.8B). Levels of HIV-1 p24 and nucleic acids in spleen measured by 
immunostaining and qPCR and RNAscope tests paralleled one another (Figures 2.6 and 
2.7B). During the equivalent infection windows, tissue HIV-1p24 expansion was more 
aggressive in hu-PBL than that in hu-HSC mice (Figure 2.8B). These data together 
confirmed that the quickly established HIV-1 infection in both models were replication-
competent and virus spread more aggressively in hu-PBL than in hu-HSC mice. 
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Figure 2. 8 HIV-1p24 expression in infected humanized mice.  
Spleen and lymph node samples were collected from (A) hu-HSC and (B) hu-PBL mice at necropsy 
then formalin fixed and paraffin embedded. Five micrometer thick sections were cut then stained 
with human HLA-DR and HIV-1p24 antibodies. Representative images from each group were 
selected and pictures were captured for both markers (shown as brown dots) from individual 
animals. Human HLA-DR images were taken at 20 x objective magnifications and HIV-1p24 
images were captured at 40 x objective magnifications.  
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Figure 2. 8 HIV-1p24 expression in infected humanized mice.  
Spleen and lymph node samples were collected from (A) hu-HSC and (B) hu-PBL mice at necropsy 
then formalin fixed and paraffin embedded. Five micrometer thick sections were cut then stained 
with human HLA-DR and HIV-1p24 antibodies. Representative images from each group were 
selected and pictures were captured for both markers (shown as brown dots) from individual 
animals. Human HLA-DR images were taken at 20 x objective magnifications and HIV-1p24 




2.4.6 Host immunity in humanized mouse models 
Different strategies of humanization shape unique cellular integrations in 
humanized mice. Previous studies observed that the engrafted human T cells in hu-PBL 
mice expressed a predominated memory/activated (CD45RO) phenotype that supports 
HIV-1 infection (126) while in hu-HSC mice approximately 50% of human T cells are 
naive (CD45RA) that are less susceptible to HIV-1 infection (121). Therefore, viral 
infection is usually more aggressive in hu-PBL mice than that in hu-HSC mice (41). In the 
current study, we also observed a similar pattern during early HIV-1 infection where virus 
was seeded at accelerated rates in hu- PBL than in HSC mice. To further characterize and 
compare the intrinsic host environment in both mouse models that may affect HIV-1 
infection, we adopted naïve hu-HSC and hu-PBL mice (n=3/group) with comparable 
human cell reconstitutions (Table 2.1). In these animals, immune-linked host gene 
expression was tested. Total RNA was isolated from individual animal spleen and a total 
of 84 gene expressions were evaluated. Overall, increases in gene expressions paralleled 
adaptive immune activation and were most prominent in hu- PBL versus HSC mice 
(Figure 2.9 and Table 2.2). Upregulated T cell genes were readily observed affecting cell 
activation (e.g. CD2, CD3, CD4, CD8, FOXP3, and LAG3), proliferation (e.g. CD28, IL2, 
IL1β, IL18, and TNFSF14), and differentiation (e.g. CD27, CD80, CD86, and IL15). Two 
major co-receptors for HIV-1 entry, CCR5 and CXCR4, were also found to be upregulated 
in hu-PBL compared to HSC mice. The elevated B cell activation and proliferation markers 
included CD27, CD40, CD80, CD81, IL2, and IL10. To investigate how these 
differentially expressed molecules may impact the host environment, we subjected the 
genes with fold changes above 2 (81/84) to Ingenuity Pathway Analysis (IPA). These tests  
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Figure 2. 9 Expression of human immune activation markers in humanized mice.  
Total RNA was isolated from uninfected humanized mouse spleens and analyzed for the expression 
of markers for human immune activation. A total of 84 genes were evaluated and compared 
between the two animal models. (A) Heatmap depicted the differentially expressed genes (for 1–
12) associated with immune activation in hu- PBL compared against HSC mice (for A–G). The 
log2 fold change of the individual gene is listed in the bottom panel. (B) Differentially expressed 
genes with log2 fold change of ≥3 are outlined that are expressed in hu-PBL spleens over what was 





Figure 2. 9 Expression of human immune activation markers in humanized mice.  
Total RNA was isolated from uninfected humanized mouse spleens and analyzed for the expression 
of markers for human immune activation. A total of 84 genes were evaluated and compared 
between the two animal models. (A) Heatmap depicted the differentially expressed genes (for 1–
12) associated with immune activation in hu- PBL compared against HSC mice (for A–G). The 
log2 fold change of the individual gene is listed in the bottom panel. (B) Differentially expressed 
genes with log2 fold change of ≥3 are outlined that are expressed in hu-PBL spleens over what was 
found in HSC mice. A complete gene list can be found in Table 2.2. 
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Table 2. 2 Changes of human gene expressions in hu-PBL compared to hu-HSC mice 
 
Gene Symbol Gene Description Fold Change 
IFNG Interferon, gamma 13.85 
LAG3 Lymphocyte-activation gene 3 11.67 
CSF2 Colony stimulating factor 2 (granulocyte-macrophage) 9.63 
CD8B CD8b molecule 9.48 
CCR3 Chemokine (C-C motif) receptor 3 9.48 
IL4 Interleukin 4 9.16 
IL12B Interleukin 12B (natural killer cell stimulatory factor 2) 9.09 
CX3CL1 Chemokine (C-X3-C motif) ligand 1 9.09 
IL10 Interleukin 10 9.05 
FASLG Fas ligand (TNF superfamily, member 6) 9.01 
IL3 Interleukin 3 (colony-stimulating factor, multiple) 8.97 
CCR2 Chemokine (C-C motif) receptor 2 8.88 
IL12RB2 Interleukin 12 receptor, beta 2 8.78 
TLR9 Toll-like receptor 9 8.76 
IL5 Interleukin 5 (colony-stimulating factor, eosinophil) 8.72 
IL12A Interleukin 12A (natural killer cell stimulatory factor 1) 8.66 
AICDA Activation-induced cytidine deaminase 8.62 
NOS2 Nitric oxide synthase 2, inducible 8.41 
CCR5 Chemokine (C-C motif) receptor 5 8.23 
IL2 Interleukin 2 8.21 
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IL2RA Interleukin 2 receptor, alpha 8.01 
CD27 CD27 molecule 7.99 
IL6 Interleukin 6 (interferon, beta 2) 7.93 
CD8A CD8a molecule 7.93 
IL11 Interleukin 11 7.9 
CD1D CD1d molecule 7.35 
TLR2 Toll-like receptor 2 7.2 
CCL3 Chemokine (C-C motif) ligand 3 7.08 
RAG1 Recombination activating gene 1 7.07 
MICB MHC class I polypeptide-related sequence B 6.94 
IL1B Interleukin 1, beta 6.84 
CD274 CD274 molecule 6.8 
CD276 CD276 molecule 6.78 
TLR6 Toll-like receptor 6 6.76 
IL7 Interleukin 7 6.7 
CXCL8 Interleukin 8 6.61 
TNFSF14 Tumor necrosis factor (ligand) superfamily, member 14 6.58 
ICOSLG Inducible T-cell co-stimulator ligand 6.5 
TLR4 Toll-like receptor 4 6.31 
CD86 CD86 molecule 6.3 
FAS Fas (TNF receptor superfamily, member 6) 6.2 
CCR1 Chemokine (C-C motif) receptor 1 6.14 
SOCS1 Suppressor of cytokine signaling 1 6.12 
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APC Adenomatous polyposis coli 6.12 
PTPRC Protein tyrosine phosphatase, receptor type, C 5.89 
IL12RB1 Interleukin 12 receptor, beta 1 5.89 
CD80 CD80 molecule 5.85 
CXCR3 Chemokine (C-X-C motif) receptor 3 5.83 
CXCR5 Chemokine (C-X-C motif) receptor 5 5.75 
CD7 CD7 molecule 5.75 
IRF4 Interferon regulatory factor 4 5.74 
IL13 Interleukin 13 5.68 
TLR1 Toll-like receptor 1 5.65 
IL18R1 Interleukin 18 receptor 1 5.62 
CCR4 Chemokine (C-C motif) receptor 4 5.39 
BLM Bloom syndrome, RecQ helicase-like 5.23 
FOXP3 Forkhead box P3 4.99 
CD28 CD28 molecule 4.76 
RIPK2 Receptor-interacting serine-threonine kinase 2 4.73 
CXCR4 Chemokine (C-X-C motif) receptor 4 4.73 
IL15 Interleukin 15 4.71 
BLNK B-cell linker 4.51 
ADA Adenosine deaminase 4.17 
CD2 CD2 molecule 4.13 
NCK1 NCK adaptor protein 1 4.05 
CD5 CD5 molecule 4.03 
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DPP4 Dipeptidyl-peptidase 4 3.99 
EGR1 Early growth response 1 3.86 
LCK Lymphocyte-specific protein tyrosine kinase 3.81 
CD3E CD3e molecule, epsilon (CD3-TCR complex) 3.72 
MAP3K7 Mitogen-activated protein kinase kinase kinase 7 3.71 
CD4 CD4 molecule 3.71 
IL18 Interleukin 18 (interferon-gamma-inducing factor) 3.62 
VAV1 Vav 1 guanine nucleotide exchange factor 3.61 
BCL2 B-cell CLL/lymphoma 2 3.42 
IL4R Interleukin 4 receptor 3.34 
CD40 CD40 molecule, TNF receptor superfamily member 5 3.24 
CD40LG CD40 ligand 2.89 
CD3G CD3g molecule, gamma (CD3-TCR complex) 2.83 
CD3D CD3d molecule, delta (CD3-TCR complex) 2.44 
CD47 CD47 molecule 2.43 
TGFB1 Transforming growth factor, beta 1 2.38 
CD81 CD81 molecule 1.45 




revealed that the top canonical pathways affected in hu-PBL over HSC mice were (1) Th1 
and Th2 activation pathway (p=4.62E-56); (2) innate and adaptive immunocyte 
communications (p=3.03E-47); (3) Th2 (p=5.58E-43); (4) Th1 (p=2.14E-42) and (5) T-
helper cell differentiation (p=1.76E-39, Figure 2.10A). All five pathways are engaged in 
T cell regulation. Downstream Effects Analysis was performed to assess regulatory 
hierarchy. A total of 500 gene-related diseases or functions each with a minimum of 10 
molecules related were predicted and top 10 functions were listed (Table 2.3). The 
differential genetic network in the hu-PBL mice was most significantly correlated with the 
activation of lymphatic systems with 80% (65/81) of the input genes involved and 83% 
(54/65) led to systemic activation responses (Figure 2.10B). A spectrum of inflammation-
associated genes was also upregulated in hu-PBL as compared to hu-HSC mice, including 
both pro-inflammatory (e.g. IL1, IL17, IFNγ, TNFα, CXCL3, and CXCL8) and anti-
inflammatory (e.g. IL4, IL6, IL10, IL12, IL13, and TNFβ) molecules (Figure 2.9 and 
Table 2.2). IPA analysis confirmed that this genetic pattern was associated with 
inflammatory responses with 67% (54/81) of the input genes involved and 81% (44/54) 
linked to cell activation pathways (Table 2.3 and Figure 2.11). Taken together, these data 
support the notion that an established immune activated and inflammatory tissue 
environment facilitates HIV-1 infection and dissemination.  
2.5 Discussion 
Early ART intervention restricts the HIV-1 reservoir size (127-129) and may achieve long-term 
viral remission in select infected individuals (50, 130). However, all patients inevitably experience 




Figure 2. 10 Gene expression patterns analysis by IPA in humanized mice.  
(A) Canonical pathway gene analyses. The stacked bar chart demonstrates the percentage of 
upregulated (red) and downregulated (green), as well as non-overlapped (white) genes from the 
prestored genebank in IPA (numbers listed at the top of each bar). The right y-axis displays the –
log of p-Value calculated by Fisher's Exact Test illustrates the significance of each canonical 
pathway. (B) Downstream biological effects prediction. The most relevant downstream effect 
predicted by IPA was lymphoid activation. A set of 65 genes that were differentially expressed 
between hu-PBL and hu-HSC mice co-regulate this pathway. The putative function was located in 
the center while the related regulator listed at the periphery. The type of interaction is indicated by 
red (prediction of activation), blue (prediction of inhibition), yellow (inconsistent), and gray 
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(A) Canonical pathway gene analyses. The stacked bar chart demonstrates the percentage of 
upregulated (red) and downregulated (green), as well as non-overlapped (white) genes from the 
prestored genebank in IPA (numbers listed at the top of each bar). The right y-axis displays the –
log of p-Value calculated by Fisher's Exact Test illustrates the significance of each canonical 
pathway. (B) Downstream biological effects prediction. The most relevant downstream effect 
predicted by IPA was lymphoid activation. A set of 65 genes that were differentially expressed 
between hu-PBL and hu-HSC mice co-regulate this pathway. The putative function was located in 
the center while the related regulator listed at the periphery. The type of interaction is indicated by 
red (prediction of activation), blue (prediction of inhibition), yellow (inconsistent), and gray 
(related, not predicted). 
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Table 2. 3 p-value ranking of top 10 Disease and Bio-Functions by IPA on differential 
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Figure 2. 11 The prediction of biological processes according to changed expression of 
humanized mouse genes by IPA was associated with  inflammatory response.  
Total spleen RNA was isolated from hu-HSC and hu-PBL mice and probed using RT2 Profiler PCR 
Array for T & B cell activation analysis. Hu-HSC mice were chosen as control group while hu-
PBL mice as test group. The fold changes of human genetic expression (hu-PBL / hu-HSC) were 
determined by SABioscience RT2 Profiler PCR Array Data Analysis software, version 3.5. IPA 
was applied for predicting the biological function based on the pattern of differentially expressed 
genes in the dataset. Inflammatory was one of the most significantly affected pathway co-regulated 
by a set of 54 genes that were differentially expressed between hu-PBL and hu-HSC mice. The 
putative function was located in the center while the related regulators listed at the periphery. The 
type of interaction is indicated by red (prediction of activation), blue (prediction of inhibition), 
yellow (findings inconsistent), and gray (known to be related, but effect not predicted). 
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infection (111). It is thus important to determine viral compartmentalization in cells and tissues. 
Nonetheless, it is not possible to accurately answer this question in an infected human. Therefore, 
in the current study we traced HIV-1 peripheral and tissue dissemination after infection in 
humanized mice used to reflect the temporal dynamics of tissue infection. The major advancements 
of this study were direct comparisons between hu- HSC and PBL mice using a dual tropic HIV-1 
strain (HIV-1ADA) in study (131). Multiple time points after HIV-1 infection to reflect a complete 
picture of early viral dynamics as well as host immune responses. By comparing the viral-host 
kinetics, we were able to identify the host factors that affect early events of HIV-1 infection. 
Limitations in accessing human samples to correlate immune responses with levels of viral growth 
were achieved through the use of humanized mice. 
Herein, two well studied chimeric humanized mouse models were used in this 
report with divergent biologic and immune characteristics. Hu-HSC mice were made after 
engrafting human CD34+ HSC into new born NSG mice (132). After cell differentiation 
and maturation, mice are reconstituted with multiple lineages of human immune cells. The 
cellular type and composition in hu-HSC mice are more similar to human (T and B cells 
and monocyte-macrophages) with a life expectancy of more than a year. Hu-PBL mice are 
produced by implanting human peripheral blood lymphocytes into the adult NSG mice. 
This leads to dominant human lymphocyte reconstitution of up to 95 % T cells within 2-3 
days (133). However, as a result of GvHD, the life span of the viral immune responses in 
these animals can only be measured for a single month. Results from both models allowed 
us not only able to trace early HIV-1 infection, but investigate how host environments may 
affect viral-host outcomes (134).   
Effector memory CD4+ T cells are the primary targets of HIV-1 and their depletion 
parallels the development of the acquired immune deficiency syndrome (125). CD4+ T cell 
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loss is observed within months of HIV-1 infection from both peripheral blood and 
lymphoid tissues (135). In the current study, we observed modest CD4+ T depletion in 
blood of hu-HSC mice as early as 3 days after infection that progressed over time. A similar 
trend was also observed in infected splenocytes and bone marrow. Altogether, such results 
indicate that human immune function is impaired at the earliest stage of infection (136). 
CD8+ T cell percentages were elevated in parallel to CD4+ T cell losses. In hu-PBL mice, 
peripheral CD4+ T cell depletion was more significant than what was observed in hu-HSC 
mice. This reflected a highly activated cell phenotype facilitating productive HIV-1 
infection and cellular degradation.  
Plasma HIV-1 RNA is first seen within three weeks after HIV-1 infection in 
humans (137, 138). Due to the difficulty of early HIV-1 screen in the clinic, a gap between 
initial viral exposure and estimated infection period is inevitable, which can be bridged 
using suitable animal models. In the current study, peripheral viral load was detected in 40% 
(2/5) of hu-HSC animals by days 3, 5, and 7 after infection each and 100% by day 14. It 
implied that peripheral viral replication might be established earlier than what is usually 
observed in humans given the possibility that highly sensitive techniques may further 
improve detection limit. In hu-PBL mice peripheral viral load was fully expressed in all 
monitored animals within 3 days of infection with a peak viremia seen at day 7. The data 
clearly support the notion that viral replication is linked to immune activation. 
Tissue HIV-1 DNA and RNA was first detected by semi-nested qPCR at 3 days 
after infection in hu-HSC mouse spleen, lung, and liver, demonstrating that infection was 
established and disseminated to multiple tissues rapidly while plasma viral load is 
extremely low or undetectable. Interestingly, at 5 and 7 days after infection, viral nuclear 
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acids were recovered from each of these tissues in 2/5 animals and supported the fact that 
all three tissue compartments were seeded by virus at the earliest stage of infection. The 
observation of HIV-1 RNA and HIV-1p24 antigen on the corresponded spleen sections 
supported that the detected virus completed its life cycle and demonstrating that spleen 
could serve as a major anatomical infectious site (139). In addition, infected cells were 
highly enriched within lymphoid follicles. This is due to the known higher numbers of 
reconstituted human cells in follicles and supports its role in early tissue infection. As the 
germinal centers are poorly developed in humanized mice, their role in viral 
compartmentalization requires further study in defining it as a sanctuary site during ART 
(140). At 14 days after HIV-1 infection, virus was easily seen in spleen, lung, liver, gut and 
kidney. Tissue viral DNA and RNA levels were dramatically increased compared to the 
early time points, accordant with plasma HIV-1 RNA. One can speculate that multiple 
peripheral and tissue sanctuaries have been established at early points after viral infection, 
which may illustrate the hurdles that need be overcome to achieve viral eradication (111). 
These observations highlight hu-HSC mice as a model for the earliest stages of HIV-1 
infection. The observations now made also support our prior works investigating cellular 
and tissue replication patterns seen during chronic infections (121). In these works virus 
was identified in bone marrow, spleen, lung, gut, brain, kidney and liver tissues as well as 
in CD34+ progenitors, monocyte-macrophages, dendritic cells, and CD4+ stem cell 
memory, naïve memory, central memory, effector memory and regulatory T cells. All were 
identified after 5 to 14 weeks of viral infection.  
Lymph nodes are major tissue compartments that harbor HIV-1 (141). In the current 
study, we did not detect HIV-1p24 in hu-HSC mouse lymph nodes until 14 days after 
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infection. This reflected, in measure, the underdeveloped lymph nodes in immune deficient 
animals (142). While gut-associated lymphoid tissue or GALT is one of the earliest 
observed infected tissue during acute HIV-1 infection (20) we also were not able to detect 
HIV-1 infection in hu-HSC mouse GALT until day 14. This was later than what was 
observed from spleen, lung, and liver. These data reflect the relatively low humanization 
operative in hu-HSC mouse GALT (143). This limitation restricts studies of viral 
transmission (144). However, even considering the limitations of the model infection of 
GALT showed high levels of infection at later time points. The low reconstitution of human 
immune cells may also explain delayed HIV-1 infection in hu-HSC mouse brains. A recent 
study reported that within early infected individuals (median 15 days), HIV-1 RNA was 
observed in cerebrospinal fluid from 83%, 15/18 infected subjects, with the earliest 
detection by 8 days (138). However, according to variant humanized mouse models studied, 
HIV-1 seeding in the central nervous system was generally much more delayed (43, 118, 
145). This discordance demonstrates some of the limitation of our current humanized 
mouse models. Of interest to the current studies are our prior experiences in using hu-HSC 
mice that showed sustained bone marrow viral burden (121, 146). Although bone marrow 
HIV-1 infection was not measured in the current study, the progressive decline of CD4+ T 
cells indicated that active viral replication was rapidly established in the hu-HSC mouse 
bone marrow. Notably and distinct from hu-HSC mice, HIV-1 was seeded into tissue 
compartments more rapidly in hu-PBL mice. At 3 days post-infection, HIV-1 DNA and 
RNA were readily detected across a wide range of tested tissues, including brains. HIV-
1p24 was also observed in the 3-day infected lymph node sections. Viral levels were higher 
in hu-PBL mice at the same time courses compared to that in hu-HSC mice. Altogether, 
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these results strengthen the notion that the host microenvironment is closely linked to early 
HIV-1 tissue replication. 
Previous studies by others showed that low levels of T cell activation and 
proliferation lead to reduced HIV-1 susceptibility (147, 148). Nevertheless, comorbid 
factors such as sexually transmitted infectious diseases substantially increased the risks of 
HIV-1 acquisition and transmission as well as affecting viral load. All are known to be 
associated with inflammation and immune activation (149-151). Our data support the idea 
that immune activation markers predict viral susceptibility in mouse models of human 
disease. Comparisons in host tissue environments were made at the transcriptional level in 
both models. These data support the idea that immune activation that occurs prior to 
infection could predict early HIV-1 infection dynamics in these animal models. In addition, 
a wide range of inflammation-associated genes was also found to be upregulated in hu- 
PBL compared to HSC mice. While pro-inflammatory conditions facilitate viral 
acquisition and promote T cell activation (152), anti-inflammatory factors serve to 
maintain systemic homeostasis. Noteworthy, a recent report demonstrated that a systemic 
proinflammatory signature was established by as early as 24 hours after SIV infection of 
rhesus macaques (114). It will be interesting to evaluate how early inflammasome activated 
in HIV-1 infection affects early viral dynamics. We posit that immune-activation and 
inflammation explains early HIV-1 infection, rapid viral dissemination and accelerated 
CD4+ T cell loss in the hu-HSC mice.   
Recently we demonstrated that hu-HSC mice infected with HIV-1NL4-3 strain (153) 
expressed high levels of HIV-1 replication in peripheral blood, gut, spleen, lung, liver, 
brain, kidney, lymph node and bone marrow. These results illustrated that viral factors also 
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affect the formation of HIV-1 infection in tissue compartments. In addition, a recent report 
found that after acute intravaginal challenge of HIV-1BaL on humanized 
Rag1KO.IL2RγcKO.NOD mice expressing HLA class II (DR4) molecule (DRAG) mice 
(118), virus was detected at certain tissues by day 4 while brain was lastly infected until 
day 21. This also suggested that different infection routes and genetic background should 
be considered in reflecting what would be operative in an infected human host. While we 
understand that the intraperitoneal route used to establish viral infection does not reflect 
what is operative during natural infection routes such as mucosal transmission. However, 
we performed this route to ensure infection was operative in 100% of challenged animals 
and was able to explore viral compartmentalization during the evolution of persistent viral 
infection. The deployment of humanized mouse models allows researchers to determine 
how, where and at what levels virus gains a foothold in tissue sites and prior to any or all 
therapeutic strategies. Indeed, based on this work, our group has shown that combinations 
of long acting slow effective release antiretroviral therapy and CRISPR-Cas9 for viral 
excision led to permanent HIV-1 elimination in up to one third of infected humanized mice 
(109) and supports the use of this model in viral eradication schemes.   
2.6 Conclusions 
In conclusion, by using humanized mouse models, our study identified a wide range 
of tissue compartments and their temporal and spatial dynamics during early HIV-1 
infection. The four major findings from this study are summarized as First, HIV-1 infection 
was identified in multiple tissue compartments as early as 3 days post-infection using 
highly sensitive detection techniques in two different humanized animal models. Second 
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HIV-1 was detected in all tissue by day 14 in hu-HSC mice. Third, tissue viral replication 
patterns were linked to markers of immune activation and immunity for each animal model 
that included T cell maturation and inflammation. Fourth, spleen, lung, and liver were 
among the earliest infected tissues and sustained heavy viral burden throughout the 
monitoring period as shown in proviral DNA amplifications. It is noteworthy that the tissue 
types listed above do not cover all the human anatomical viral sanctuaries. Others tissues 
that require analyses in humanized mice include but not limited by thymus, male and 
female reproductive tract, skin, and adipose tissue (18, 154). Even accepting the limitation 
of both models and underdevelopment of secondary lymphoid tissues this information will 
instruct us on the guideline of early ART intervention and development of tissue-specific 
ART. It has been an intriguing question whether a window exists for ‘HIV-1 cure’, if ART 
is administrated soon after viral exposure to maximize the restriction of viral replication 
followed by combinational strategies targeting the residual proviral DNA. Using 
humanized mouse model under controlled conditions, we will be able to answer this 
question, which will benefit the translation of clinical investigation.  
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Chapter 3 Combination of LASER ART and CRISPR-Cas9  




   Human immunodeficiency virus (HIV-1) eradication can be achieved by 
complete elimination of viral reservoirs from host cell and tissue sanctuaries. Success of 
HIV-1 eradication can be affirmed through the absence of viral rebound after cessation of 
antiretroviral therapy (ART). Here we demonstrate, for the first time, that sequential 
treatment of HIV-1 infected humanized mice with long-acting slow-effective release ART 
(LASER ART) followed by viral CRISPR-Cas9 excision achieved viral eradication in up 
to a third of infected dual treated humanized mice. In these HIV-1 eradicated mice, 
ultrasensitive nested and digital droplet PCR and RNAscope assays did not detect virus in 
blood, spleen, lung, kidney, liver, gut-associated lymphoid tissue, and brain. Excision of 
proviral HIV-1 DNA fragments spanning the LTRs and the Gag gene by CRISPR-Cas9 
was seen in the absence of off-target effects and viral rebound following ART cessation 
and CD4+ T cell restoration. Adoptive transfer of lymphoid cells, from dual-treated virus-
free animals, to uninfected humanized mice or by direct co-cultivation with mitogen 
stimulated lymphocytes failed to recover infectious progeny virus. In contrast, replication 
competent HIV-1 was readily detected in all infected animals treated with ART or 
CRISPR-Cas9 alone. Thus, sequential LASER ART and CRISPR-Cas9 therapies 
administered to HIV-1 infected humanized mice provide the first proof-of-concept that 
viral sterilization is possible. 
3.2 Introduction 
According to UNAIDS, by 2018 more than 37.9 million people worldwide were 
living with the human immunodeficiency virus type one (HIV-1) and 1.7 million people 
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were newly infected. Among infected individuals, 23.3 million (62%) people had access to 
antiretroviral therapy (ART). While ART restricts various steps of the hiv-1 life cycle, 
including cellular entrance, reverse transcription, genome integration, and viral assembly, 
it fails to eliminate integrated HIV-1 proviral DNA (155, 156). Even though majority of 
proviral DNA that recombines into host genome is defective, some replication-competent 
HIV-1 DNA maintains latent infection in cellular and tissue reservoirs and ready to be 
reactivated upon ART interruption and causes HIV-1 resurgence (157). HIV-1 reservoirs 
have become the major obstacle to viral cure, alongside a combination of factors including 
inadequate ART to viral reservoirs, less efficient cytotoxic lymphocyte killing, rapid viral 
spread and mutations. By far, successful HIV-1 eradication has only been achieved in two 
cases who experienced aggressive chemotherapy and bone marrow transplantation from 
donors with CCR5 mutation (47, 48). The success in these individuals likely resulted from 
the clearance of majority if not all of HIV-1 reservoirs and with newly transplanted cells 
that are intrinsically resistant to viral infection. However, this procedure is very dangerous 
and cannot be extended as a regular therapy for millions of HIV-1 infected individuals. 
Other current cure strategies that covered latency reversal agents, broadly neutralizing 
antibody, therapeutic vaccine, chimeric antigen receptor T cells and immune enhancers 
have not been able to achieve long-term suppression in patients after stopping ART (52, 
53, 158-160). To address this dilemma, we conducted a proof-of-concept study using state-
of-art long-acting nanoformulation of ART and CRISPR-Cas9 gene editing technology to 
pursue HIV-1 eradication from humanized mouse model. The long-acting highly 
hydrophobic lipophilic antiretroviral prodrugs were named long-acting slow-effective 
release ART (LASER ART). These LASER ARTs demonstrated enhanced drug half-life, 
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cellular up-take and retention, penetration across cell and tissue barriers and improved 
control against ongoing viral infection (44, 161-164). While HIV-1 replication was 
effectively inhibited, CRISPR-Cas9 was employed to excise integrated viral copies. 
CRISPR-Cas9 technology has grown rapidly and shown promise in treatment of multiple 
genetic diseases including cancer, blindness, muscular dystrophy, and HIV-1/AIDS. 
Indeed, CRISPR-Cas9 that was designed to specifically target conserved HIV-1 sequences 
have successfully excised HIV-1 fragments from the host genome in cell cultures and in 
tissues from small animal models of HIV-1 infection (107, 165-169). To this end, we tested 
whether or not a combination of LASER ART and CRISPR-Cas9 treatments would work 
“in synergy” for viral elimination. Using HIV-1 infected humanized mice, we 
demonstrated that a complete viral eradication was achieved in a subset of animals that 
received LASER ART and CRISPR-Cas9 dual treatment. Viral elimination was 
exhaustively scrutinized by nested and digital PCR, RNAscope, and in vitro and in vivo 
viral outgrowth assay using seronegative healthy donor PBMCs and naïve humanized mice, 
respectively. While HIV-1 was not detected in all these tests from ‘cured’ animals, virus 
was observed in all other HIV-1 infected humanized mice that received LASER ART or 
CRISPR-Cas9 treatment alone. We demonstrate that HIV-1 can be eradicated using this 
combinational strategy of LASER ART and CRISPR-Cas9.  
3.3 Materials and Methods 
3.3.1 Generation and HIV-1 infection of humanizded mice  
NSG mice were obtained from the Jackson Laboratories, Bar Harbor, ME and bred 
under specific pathogen-free conditions at the University of Nebraska Medical Center 
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(UNMC). Human CD34+ HSC were enriched from human cord blood or fetal liver cells 
using immune-magnetic beads (Miltenyi Biotec Inc., Auburn, CA, USA). Cells were 
intrahepatic injected into newborn NSG mice after irradiation at 1 Gy using a RS‐2000 X‐
Ray Irradiator (Rad Source Technologies, Buford, GA). Human cell reconstitution was 
evaluated by flow cytometry (120, 170). At the age of 18 weeks, humanized mice with 
comparable human cell levels were intraperitoneally infected with HIV-1NL4-3 or HIV-1ADA 
(43, 171) at 104 TCID50/ml. Plasma viral RNA levels (copies/ml) were analyzed using the 
automated COBAS Ampliprep System V2.0/Taqman-48 system (Roche Molecular 
Diagnostics, Basel, Switzerland) (120, 171). For this assay, 100 μl of mouse serum was 
diluted to 1 ml with sterile filtered normal human serum. The detection limit of the assay 
is 200 viral RNA copies/ml. 
3.3.2 Synthesis of nanoformulated antiretroviral drugs  
Dolutegravir (DTG), lamivudine (3TC), and abacavir (ABC) were generously 
provided by ViiV Healthcare, Research Triangle Park, NC. Rilpivirine (RPV) was 
purchased from Hangzhou Bingo Chemical Co., Ltd, Hangzhou, China. Parent 
antiretroviral drugs DTG, 3TC, and ABC were myristoylated into prodrugs and named as 
MDTG, M3TC, and MABC. These three prodrugs were encased into poloxamer 407 (P407) 
and RPV was encased into poloxamer 338 (P338) in native form. All drugs were 
formulated into nanosuspensions using high pressure homogenization as previously 
described (44, 161, 162). Final drug concentrations for injection were determined by 
HPLC-UV/Vis and UPLC-MS/MS and intramuscularly injected to humanized mice. 
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3.3.3 Antibodies for flow cytometry 
Humanized mice were bled through submandibular vein longitudinally to track 
human cell levels. Animal blood was collected using ethylenediaminetetraacetic acid 
(EDTA)-coated tubes or by cardiac puncture at animal sacrifice. Flow cytometry staining 
employed a five-color panel to label human CD45, CD3, CD4, CD8, and CD19 markers 
using FITC-conjugated mouse anti-human CD45 (555482), Alexa Fluor 700-conjugated 
mouse anti-human CD3 (557943), APC-conjugated mouse anti-human CD4 (555349), 
BV421-conjugated mouse anti-human CD8 (562428), and PE-Cy5-conjugated mouse 
antihuman CD19 (555414) antibodies; all antibodies were purchased from BD Biosciences, 
San Jose, CA. Antibodies. Flow cytometry tests were operated using LSR-II FACS 
analyzer (BD Biosciences) and analyzed by a FlowJo (BD Immunocytometry Systems, 
Mountain View, CA, USA). 
3.3.4 Tissue HIV-1 analysis by semi-nested qPCR 
Humanized mouse tissues (spleen, bone marrow, lung, gut, liver, kidney, and brain) 
were collected at sacrifice and total HIV-1 DNA and RNA were extracted using a Qiagen 
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Total HIV-1 
DNA isolated from ACH2 cell line which contains one HIV-1 DNA copy per cell was 
serially diluted and used as standard control. Human CD45 gene were used as human cell 
marker for normalization (Thermo-Fisher Scientific). HIV-1 RNA was first reverse 
transcribed into cDNA using SuperScript III (Invitrogen, MA, USA) at 42 °C for 60 min.  
HIV-1 cDNA and total DNA were subjected to semi-nested qPCR and ddPCR assays for 
quantification as previously described (43). The first round of PCR was performed on a 
conventional PCR machine (T100 Thermal Cycler, Biorad, CA, USA) in 25 μl of PCR 
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reaction mix containing 500 ng of template and 50 ng each of both primers annealing to 
HIV-1 gag region; the reaction conditions are as follows: 94 °C for 3 min, followed by 15 
cycles of 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min. The product of the first PCR 
was subsequently used as a template in the second semi-nested real-time PCR amplification 
performed on the ABI Step One Plus real-time PCR machine (Applied Biosystems, Foster 
City CA, USA) using TaqMan detection probe and primers (172). Two μl of the first PCR 
product was diluted to 50 μl with PCR master mix containing two primers at 0.2 μM each 
and 0.2 µM TaqMan dual-labeled fluorescent probe. Real-time PCR settings were as 
follows: 50 °C for 2 min, then 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s 
and 60 °C for 1 min. The amplicon sizes are 221 bp for the first round of PCR and 83 bp 
for the second round (real-time) PCR. DNA extracted from ACH2 cells containing one 
integrated copy of HIV-1 per cell was used as standard in serial 10-fold dilutions with HIV 
copy numbers ranging from 101 to 105 DNA copies/reaction (43, 173). Semi-nested real-
time RT-PCR on HIV-1 RNA was performed as described (43, 173).  
3.3.5 Detection of tissue HIV-1 nucleic acids by ddPCR 
ddPCR was performed based on the water–oil emulsion droplet technology, using 
the ddPCR™ Supermix for Probes reagents in the QX200™ Droplet Digital™ PCR system 
(Bio-Rad Laboratories, Hercules, CA, USA). For quantification of HIV-1 DNA, the eluted 
cellular DNA was PCR amplified (43, 173, 174) targeting the HIV-1 gag gene using the 
outlined primers targeting HIV-1 gag gene (Forward-5'-
TCAGCCCAGAAGTAATACCCATGT-3' and Reverse-5'-CACTGTGTTTAGC 
ATGGTGTTT-3') and a TaqMan probe (5’ FAM-ATTATCAGA 
AGGAGCCACCCCACAAGA-3’ IBFQ). A total of 100-200 ng DNA from each tissue 
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was used as a template for ddPCR amplifications with the same thermal cycling conditions 
used for real-time q-PCR detection. Data acquisition and analysis were done using QX200 
droplet reader and QuantaSoft™ software provided with the instrument.  
3.3.6 Viral recovery by in vitro viral outgrowth assay 
Human PBMCs were collected from HIV-1,2 seronegative donors and cultured 
with PHA and IL-2 containing 10% RPMI (128, 175, 176). Humanized mouse splenocytes 
and BM were isolated and separately co-cultured with PBMCs at concentrations of (1:5). 
Eight days later, cells were collected and HIV-1 RNA and DNA were extracted for 
downstream qPCR analysis as described above. 
3.3.7 Viral recovery by in vivo viral outgrowth assay  
Humanized mouse splenocytes and BM cells were collected at sacrifice and 
homogenized and counted using TC-20 automated cell counter (Bio-Rad). A total of 8-10 
x 106 either splenocytes or BM were adoptively transferred into naïve humanized mice 
intraperitoneally. Recipient animals were maintained for 4 weeks before sacrifice and 
tissue and peripheral HIV-1 levels were evaluated as described above. 
3.3.8 Study Approval 
All experimental protocols that use laboratory animals were approved by the 
UNMC Institutional Animal Care and Use Committee ensuring the ethical care and use of 
laboratory animals in experimental research. All animal studies were performed in 
compliance with UNMC institutional policies and NIH guidelines for laboratory animal 
housing and care. Human blood cells were isolated by leukapheresis from HIV-1/2 and 
hepatitis seronegative donors and were deemed exempt from approval by the Institutional 
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Review Board of the University of Nebraska Medical Center. Human CD34+ 
hematopoietic stem cells were isolated from umbilical cord blood and are exempt from 
UNMC IRB approval. 
3.3.9 Statistics 
Data were analyzed using GraphPad Prism 7.0 software (La Jolla, CA, USA) and 
presented as the mean ± the standard error of the mean (SEM). Experiments were 
performed using a minimum of three biologically distinct replicates. For comparisons of 
two groups, Student’s t test (two-tailed) was used. Tissue drug levels, HIV-1 RT activity, 
HIV-1p24 antigen staining, T cell populations, viral RNA and DNA, and viral load were 
analyzed by one-way ANOVA with Bonferroni correction for multiple-comparisons. For 
studies with multiple time points, two-way factorial ANOVA and Bonferroni’s post-hoc 
tests for multiple comparisons were performed. Animal studies included a minimum of six 
animals per group. Extreme outliers beyond the 99% confidence interval of the mean and 
3-fold greater than the SEM were excluded. Significant differences were determined at P 
< 0.05. 
3.4 Results 
3.4.1 Viral and immune profiles of HIV-1 infected LASER ART and CRISPR-Cas9 treated 
humanized mice 
Hematopoietic stem cells (HSC) reconstituted NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
(NSG) mice exhibiting matured T cells that are broadly susceptible to HIV-1 infections has 
served a suitable model to investigate long terms viral infections and viral reservoir (45, 
120, 169, 172, 177-180). To establish this model for our studies, after irradiation of NSG 
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mice at birth, animals were engrafted with human CD34+ HSC isolated from cord blood 
by intrahepatic injection. The presence of human immunocytes in blood was evaluated by 
flow cytometry for times up to 20 weeks. After humanization was confirmed, animals were 
infected with HIV-1 (NL4-3 or ADA) at 104 tissue culture infection dose50 
(TCID50)/animal. In the initial experiment, 29 humanized mice were infected with HIV-
1NL4-3 for two weeks (Figure 3.1A). Moderate CD4+ T cell depletion was observed (Figure 
3.1B) and plasma HIV-1 RNA was established at a median of 2.2 x 105 copies/ml (Figure 
3.1C). Then animals were randomly distributed into four groups as followed: the first group 
(n = 6) was HIV-1 positive control, the second group (n = 6) received a single intravenous 
(IV) injection of AAV9-CRISPR-Cas9 at 10
12 GC (genome copy); the third group (n = 10) 
were administered LASER ART containing 45 mg/kg parent drug equivalents of NRPV 
and MDTG, and 40 mg/kg parent drug equivalents of M3TC and MABC nanoparticles by 
intramuscular injection, the fourth group (n = 7) received LASER ART followed by AAV9-
CRISPR-Cas9. At eight weeks after the last injection of LASER ART which equaled to 
five weeks post the administration of AAV9-CRISPR-Cas9, animals were sacrificed to 
evaluate the dynamic changes of immune and viral profiles (Figure 3.1A). In groups 1 and 
2 where LASER ART was not administered, peripheral CD4+ T cells dropped dramatically 
to < 6% and 15 ± 6%, respectively. In contrast, when LASER ART was present with or 
without CRISPR-Cas9 as shown in groups 3 and 4, peripheral CD4+ T cells were preserved 
at 68 ± 15% and 90 ± 7%, respectively (Figure 3.1B). Humanized mice in groups 1 and 2 
remained highly infected throughout the study. In group 3, although plasma viral load was 
significantly decreased to undetectable level after LASER ART administration but all 10 
animals experienced viral rebound after treatment interruption as observed in the clinic. In 
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group 4 where animals received dual treatment, 5 out of 7 animals experienced viral 
rebound after treatment was discontinued but 2 animals remained undetected at animal 
sacrifice (Figure 3.1C). Consistent human cell levels as shown by human CD45+ (Figure 
3.1D) and CD3+ T cells (Figure 3.1E) was monitored throughout the study. 
3.4.2 HIV-1 elimination from dual-treated humanized mouse tissue compartments 
HIV-1 DNA and RNA were extracted from animal tissues (spleen, BM, gut, brain, liver, 
kidney, and lung) from all 4 groups. Viral levels were first determined by semi-nested real-
time qPCR (Figure 3.2A and B). Tissue HIV-1 DNA and RNA replication were 
significantly lower in dual-treated animals compared to animals without treatment, or 
animals receiving treatment of either LASER ART or CRISPR-Cas9 alone. In animals 
M4346 and M4349, HIV-1 DNA and RNA were not detected in all the tissues tested 
(Figure 3.2A and B, as shown in red square). Absence of HIV-1 replication in M4346 
and M4349 was also confirmed using droplet digital PCR (ddPCR). While HIV-1 DNA 
was not detected in these 2 animals within all tested tissues, HIV-1 DNA was observed in 
all other animals (Figure 3.3A and B). Humanized mouse splenocytes and BM were 
further cocultured with phytohemaglutinin/interleukin-2 (PHA/IL-2)-stimulated peripheral 
blood mononuclear cells (PBMCs) for 2 weeks to recovery HIV-1 from latent reservoirs. 
Cells were collected at end point and tested for cell-associated HIV-1 DNA and RNA. 
HIV-1 was not recovered from cells of M4346 and M4349 but readily recovered from all 
other tested animals (Figure 3.3C and D).  
3.4.5 Cross validation for HIV-1 eradication using LASER ART and CRISPR-Cas9 















































































































Figure 3. 1 Humanization and plasma viral load of HIV-1 infected and treated humanized 
mice.  
The study scheme is shown in (A) where humanized mice were infected with 104 TCID50 of HIV-
1NL4–3 followed without treatment or with treatments of either LASER ART or CRISPR-Cas9 alone 
or both. Peripheral human CD4+ T cells (B), CD45+ cells (D), and CD3+ cells (E) were monitored 
by flow cytometry throughout the study. (C) Plasma viral load was determined by the COBAS 
























































Figure 3. 2 Tissue HIV-1 DNA and RNA in HIV-1 infected and treated humanized mice. 
 (A) HIV-1 DNA and (B) HIV-1 RNA were extracted from humanized mouse spleen, bone marrow, 
gut, brain, liver, kidney, and lung and subjected to semi-nested qPCR assays. HIV-1 DNA and 
RNA levels of individual animal were listed and expressed as total HIV-1 DNA (A) and HIV-1 
RNA (B) copies/106 human CD45+ cells. Two animals from dual treatment group, M4346 and 
M4349 showed absence of HIV-1 DNA and RNA in all the tissues (shown as red squares below 
the detection limit of 10 viral copies). One-way ANOVA and Bonferroni’s post-hoc tests were used 
to compare multiple groups. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.  
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 Figure 3. 3 Confirmation of HIV-1 absence from sterilized humanized mice by ddPCR and 
in vitro viral outgrowth assay.  
ddPCR was applied to detect low level of HIV-1 DNA in spleen of humanized mice of all 4 groups 
(A) and various organs of the dual-treated animals (B). M4346 and M4349 showed no sign of HIV-
1 replication presented as dots below the detection limit of 2 viral copies. Data were expressed as 
the mean  SEM. Bone marrow (BM) cells and splenocytes were isolated from humanized mice 
from different groups and co-cultivated with PHA/IL-2 stimulated human PBMCs. Cells were 
harvested after 14 days of co-culture and analyzed for cell-associated HIV-1 DNA (C) and HIV-1 
RNA (D). Virus failed to be recovered from M4349 (M4346 was not tested due to sample 
unavailability) but able to be recovered from all other tested animals. Data are expressed as viral 
copies/106 human CD45+ cells and presented as the mean  SEM. 
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and CRISPR-Cas9, we conducted a replicate study using a macrophage tropic viral strain 
(HIV-1ADA) infected humanized mice (Figure 3.4A). Animals were infected with 10
4 
TCID50 of HIV-1ADA for two weeks when plasma HIV-1 RNA was readily detected at a 
median level of 8.4 x104 copies/ml (Figure 3.4C). Peripheral CD4+ T cells did not show 
significant change at this point (Figure 3.4B). Infected animals were randomly divided 
into two groups, the HIV-1 control group (n = 4) and the dual-treatment group receiving 
sequential administration of LASER ART and CRISPR-Cas9 (n = 6). Animals were 
monitored for 9 weeks after cessation of LASER ART which equaled to 8 weeks after 
single injection of CRISPR-Cas9 before sacrifice. Continuous viral replication was 
observed in untreated animals alongside with decreased peripheral CD4+ T cell level to 
48.3  4.5%. In contrast, peripheral CD4+ T cells were well preserved in dual-treated 
animals at 71.3  3.5%. Notably, 3/6 animals that received LASER ART and CRISPR-
Cas9 demonstrated no viral rebound (Figure 3.4C). Tissue HIV-1 amplification was 
determined by semi-nested qPCR (Figure 3.4D). Notably, out of 3 animals that were 
negative in the peripheral only 2 animals remained negative across multiple tissues while 
1 animal presented active tissue viral replication. This emphasized the important role of 
tissue HIV-1 sanctuary even under efficient treatment.  
To further confirm a complete HIV-1 elimination from humanized mice. We 
applied in vivo viral outgrowth assay (VOA) by adoptively transferring animal splenocytes 
and BM cells from all 4 groups into naïve humanized mice. This murine-based VOA has 
been proved to be more sensitive than cell culture-based VOA on evaluating HIV-1 latency 
(181). To this end, splenocytes and BM from 2 animals from HIV-1 control groups, 1 



































































































Figure 3. 4 Validation of HIV-1 elimination in humanized mice treated with LASER ART 
and CRISPR-Cas9.  
(A) Replication study was designed. (B) Peripheral human CD4+ T cells and (C) plasma viral loads 
were monitored throughout the study. Plasma HIV-1 RNA in dual-treated animals was suppressed 
to undetectable levels after LASER ART was initiated. After treatment interruption, 3 animals 
experienced viral rebound (green to red) and 3 remained negative (green). (D) Tissue HIV-1 DNA 
was determined by semi-nested qPCR assays and data were expressed as total HIV-1 DNA 
copies/106 human CD45+ cells. In dual-treated animals, M3319 and M3336 remained tissue viral 
negative consistent with negative plasma viral load (shown in red squares). In M3324 which 
presented negative plasma viral load, tissue HIV-1 replication was positive (shown in half-red-half-














2 potential ‘cured’ animals) were engrafted into 16 uninfected humanized mice (8 for 
splenocytes transplant and 8 for BM transplant). Recipient animals were maintained for 30 
days to observe HIV-1 recovery. Two BM recipients died at study end while the rest 
remained healthy. Animals that received splenocytes or BM from M3319 and M3336 failed 
to recover HIV-1 according to viral assessment from both peripheral and tissue systems. In 
contrast, HIV-1 was detected in animals engrafted from all other donors including M3324 
(Figure 3.5). This result demonstrated that HIV-1 was completed eradicated from M3319 
and M3336. 
3.4.6 Improved efficacy of HIV-1 sterilization through sequential LASER ART and dual 
AAV9-CRISPR-Cas9 treatments of infected humanized mice  
The β-chemokine receptor type 5 (CCR5) is a major coreceptor that mediates 
macrophage-tropic HIV-1 entry of immune cells (182, 183). About 1% of European 
possess a 32-base-pair deletion in the CCR5 coding region (CCR5Δ32) that render them 
resistance to CCR5-tropic HIV-1 infection (184, 185). More importantly, to date, the only 
two cases of HIV-1 cure were achieved through allogeneic stem cell transplantation from 
CCR5Δ32 donors (47, 48). While bone marrow transplantation is highly risky and cannot 
be introduced as a regular therapy, genomic edition of CCR5 has therefore become a 
promising strategy for HIV-1 eradication. The first clinical trial employed zinc finger 
nucleases (ZFNs) to modify CCR5 on autologous CD4+ T cells and refused them back to 
patients. The study proved the safety of this procedure and modified CD4+ T cells showed 
resistance to viral infection and sustained for a long period of time in participants (103). In 
vitro modification of primary T cells, hematopoietic stem cells (HSCs), or induced 



















Figure 3. 5 Confirmation of HIV-1 elimination from humanized mice using muring-based 
viral outgrowth assay.  
At animal sacrifice, splenocytes and BM cells were isolated from donor animals from HIV-1 
control, LASER ART alone, and dual-treatment groups. Splenocytes and BM were separately 
adoptive transferred into naïve humanized mice for viral recovery. The recipient animals were 
sacrificed at 30 days after engraftment with viral levels measured for HIV-1 DNA in (A) spleen, 
(B) BM, and (C) lung, and (D) HIV-1 RNA in spleen using semi-nested qPCR with the detection 
limit of 10 viral copies. (E) Recipient spleen HIV-1 DNA was also evaluated using ddPCR with 
the detection limit of 2 viral copies. (F) Plasma HIV-1 RNA was analyzed using COBAS 
Ampliprep-Taqman-48 V2.0 assay with a sensitivity of 200 copies/ml. In all the tests, virus 
was not detected in recipient animals engrafted from M3319 and M3336 as shown in red 
square. HIV-1 can be detected in all other recipient animals adoptively transferred from other 
donors including M3324 that showed negative plasma viral load but positive tissues viral 
replication (as shown in half-red-half-black square). The green dots in (F) indicates plasma viral 
load of recipients engrafted from the LASER ART alone donor.    
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disruption and conferred HIV-1 resistance in humanized mice (104, 105, 186). By far, 
direct administration of CRISPR-Cas9 targeting CCR5 in vivo has not been tested. To this 
end, we evaluated a sequential LASER and dual CRISPR-Cas9 system (one targets HIV-1 
LTR and Gag and the other targets human CCR5) in eradication of HIV-1 from infected 
humanized mice. Similar to previous study design, we deployed a total of 28 hu-HSC 
reconstituted NSG mice and infected them with 104 TCID50 of HIV-1ADA for two weeks 
(Figure 3.6A). At this point, there was no significant change of peripheral CD4+ T-cells 
(Figure 3.6B). Plasma VL was readily established in all animals at a mean 1.8 x 104 HIV-
1 RNA copies/ml (Figure 3.6C). Animals were then randomly distributed into four groups. 
The first group (n = 7) of mice were left untreated (HIV-1 control), the second group (n = 
7) received dual intravenous (IV) injection of CRISPR-Cas9 (one AAV6-CRISPR-Cas9 
targeting CCR5 and the other AAV9-CRISPR-Cas9 targeting HIV-1 LTR and Gag), both 
at 1012 GC (genome copy) units, with a volume of 50 μl each; the third group (n = 4) were 
administered LASER ART as previously that consisted of 45 mg/kg parent drug 
equivalents of NRP and myristoylated DTG, and 40 mg/kg parent drug equivalents of 
myristoylated 3TC and ABC nanoparticles by intramuscular (IM) injection. A fourth group 
(n = 10) received LASER ART followed by two CRISPR-Cas9 injections. After LASER 
ART was initiated, plasma VL was rapidly decreased until undetectable levels in animals 
from groups 3 and 4. Plasma VL continued to elevate from groups 1 and 2 animals (Figure 
3.6C). Correspondingly, peripheral CD4+ T cells remained protected in animals from 
groups 3 and 4 but decreased in groups 1 and 2 (Figure 3.6B). Six weeks following the 
last administration of LASER ART and four weeks after the second CRISPR-Cas9 




Figure 3. 6 Plasma viral load, peripheral CD4+ T cells, and tissue HIV-1 DNA in infected and 
treated humanized mice.  
Mice were infected with 104 TCID50 of HIV-1ADA followed by treatments with LASER ART, dual 
CRISPR-Cas9 or both. (A) The study scheme shows the times of infection and treatments. After 
confirmation of viral infection, 28 infected humanized mice were subdivided into four groups. The 
first group (n = 7, red) were left untreated (control); the second group (n = 7, black) received two 
individual intravenous (IV) dose of CRISPR-Cas9 targeting human CCR5 and HIV-1 LTR/Gaga 
(1012 units each), respectively, at seven and eight weeks after viral infection, respectively; the third 
group (n = 4, blue) were administered LASER ART (NMDTG and NRPV at 45 mg/kg and 
NMABC and NM3TC at 40 mg/mg) by intramuscular (IM) injection two weeks after viral infection, 
the fourth (n = 10, green) were given LASER ART (as in group 3) followed with 2 IV injection 
CRISPR-Cas9 (as in group 2). At 17 weeks after infection, which was equivalent to 10 weeks after 
LASER ART intervention and 9 weeks after second dose of CRISPR-Cas9, animals were sacrificed 
to evaluate viral rebound. (B) Dynamic changes of peripheral human CD4+ T cells from all the 
animals were measured by flow cytometry. (C) Dynamic changes of plasma VL from all the 
animals were determined by the COBAS Ampliprep-Taqman-48 V2.0 assay with a sensitivity of 
200 copies/ml once adjusted to the plasma dilution factor. Viral RNA rebound was observed at the 
study end in all 4 LASER ART alone treated animals. In dual treated animals HIV-1 rebound was 
observed in 5 out of 10 animals but not from the other 5 animals. (D) HIV-1 DNA from spleen, 
lung, and BM of all the animals were evaluated by ultrasensitive semi-nested real-time qPCR assays. 
The individual dot represents each of the animals from four groups. The data are expressed as total 
HIV-1 DNA copies/106 human CD45+ cells. In dual treated animals, HIV-1 DNA was below the 
detection limit in 5 out of 10 animals (shown by the red squares below the dashed lines), which 
was considered sterilization of virus. 
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in the rest of dual-treated animals and all 4 animals receiving LASER ART alone. Eleven 
weeks after LASER ART interruption, another 4 dual-treated animals making it a total 5 
out of 10 (50%) animals viral rebound was observed while the other 5 out of 10 (50%) 
remained undetected. In contrast, all 4 animals that were treated with LASER ART alone 
experienced viral rebound. Animals remained readily infected in group 1 and 2 (Figure 
3.6C).  As HIV-1 came back, peripheral CD4+ T cells continued to drop in all the groups 
with a mean level of 43% ± 8, 59% ± 4, 53% ± 8, and 62% ± 4 at sacrifice from group 1 
to4, respectively (Figure 3.6B). Viral clearance was further determined in animal tissues 
tested (spleen, lung, and BM), HIV-1 DNA was absent in the 5 animals that showed 
negative plasma VL but was detected in all other animals (Figure 3.6D). Further 
confirmation of HIV-1 eradication from these animals is ongoing including viral 
assessment from other tissue types (brain, gut, liver, kidney, and lymph nodes) as well as 
viral recovery using humanized mice based viral outgrowth assay as previously described. 
3.5 Discussion 
Although considerable progress has been made during the thirty-six years of HIV-
1 research, this once lethal pathogen can be well managed under effective ART while an 
HIV-1 ‘cure’ has not been realized. The major barrier to HIV-1 eradication lies on the 
broad cellular and tissue viral reservoirs that are resistant to ART and other immune 
surveillance. It is commonly accepted that a complete HIV-1 cure cannot be achieved until 
all viral reservoirs are cleared. Researchers have employed different strategies targeting 
HIV-1 latency including early ART intervention, latency reversal agents, immune 
enhancers, broadly neutralizing antibodies. However, thus far, successful HIV-1 
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eradication has only been realized in 2 patients who received aggressive bone marrow 
transplant. The difficulties of eliminating HIV-1 reservoirs are attributed to multiple factors 
including lack of proper animal models, insufficient ART penetration, inadequate latency 
reverse, incompetent CTL function, inability of targeting integrated proviral DNA, and 
viral mutation. To partially overcome these challenges, we first adopted human CD34+ 
HSC-reconstituted mice where both myeloid and lymphoid lineages human immune cells 
can be established (43, 116, 120, 132, 171-173, 187-189). Indeed, our lab as well as other 
labs have applied these mice models to study HIV-1 pathogenesis, immunology, therapy, 
and eradication that significantly extend our understanding of this disease (43-45, 116, 173, 
190). The longevity of these humanized mice with consistent human cell levels allow 
longitudinal studies of viral and host interaction and evaluate the effects of therapeutic 
intervention in a long life span (44, 45, 161, 162, 164, 191-193). Therefore, in the current 
study we employed this mouse model to investigate a combinational strategy for potential 
HIV-1 eradication (44, 45, 161, 164, 192, 194, 195). In addition, from previous study, we 
identified acute HIV-1 infection pattern in this mouse model and demonstrated that by 2 
weeks HIV-1 infection is readily established in both peripheral and tissue system (196). 
Based on this discovery, we elected day 14 as the time point to start ART intervention.  
The second factor that may lead to the success of HIV-1 elimination in the present 
study is LASER ART. Compared to conventional ART, LASER ART was designed to 
improve hydrophobicity and lipophilicity that can establish  drug depots in tissue-residing 
macrophages to enhance drug sustention and tissue penetration (163, 164, 189, 197-202). 
In this manner, LASER ART has shown superior tissue concentrations and inhibition of 
HIV-1 replication in a longer period of time compared to conventional ART. This will 
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further limit the size of HIV-1 reservoir which provides optimal setting for subsequent 
proviral excision (116, 164, 190). Next, gene editing was employed to overcome the major 
limitation of LASER ART that none of current ART targets integrated HIV-1 genome in 
the host. To this end, we selected CRISPR-Cas9 and employed a dual-gRNA system that 
target conserved HIV-1 LTR and Gag sequences. In this manner, Cas9 endonuclease is 
able to cleave the entire viral genome from host genome. Indeed, from both cell culture 
and animal model of HIV-1 infection, the entire removal of viral sequence was achieved 
while viral production was mitigated (165, 168). Notably, CRISPR-Cas9 alone was not 
able to eliminate HIV-1 infection which may result from outnumbered virus and less 
efficient delivery method. This can be compensated by LASER ART which limits required 
targets and therefore works in synergy with CRISPR-Cas9 to eliminate HIV-1 infection. 
In the current report, we proved that HIV-1 eradication is possible using a 
combinational strategy of sequential administration of LASER ART and CRISPR-Cas9. 
This was achieved and successfully repeated in two independent studies. Interestingly, 
from both experiments, HIV-1 was eliminated from up to one third of animals that received 
dual treatment. A complete viral sterilization was exhaustively tested by long-term 
treatment interruption, plasma viral load, sensitive semi-nested qPCR, ddPCR, RNAscope, 
and in vitro and in vivo VOA. Notably, in one animal that showed negative plasma viral 
load, tissue HIV-1 tests were positive and subsequent adoptive transfer demonstrated that 
the virus were replication-competent. This emphasizes tissue HIV-1 replication could be 
more resistant to treatment and contribute to viral rebound after ART is discontinued. This 
may explain the failure of viral control in patients that stopped ART even when peripheral 
HIV-1 was below the detection limit. 
 94 
In summary, for the first time, we achieved a complete HIV-1 eradication from 
infected animal model which was likely attributed to a combination of factors evolving a 
suitable animal model, low viral set points, enhanced ART (LASER ART) with better viral 
control and latency target, and precise excision of viral sequence by CRISPR-Cas9. We 
posit that this could be a pathway leading to eventual HIV-1 eradication. Every 
modification on each component of this strategy may further improve the viral ‘cure rate’. 
We believe this proof-of-concept study will open new doors to HIV-1 eradication. 
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Chapter 4 Amplification of Replication Competent HIV-1 by Adoptive 




Detection of latent human immunodeficiency virus type one (HIV-1) in infectious 
viral reservoirs during antiretroviral therapy (ART) is a requirement for viral elimination. 
Such detection schemes require sensitive assays that require induction of replication 
competent virus in infectious tissue compartments. While viral outgrowth assays have, in 
part, filled such a need they are insensitive and often fail to detect low-levels of replication 
competent virus. To overcome this limitation, we used naïve humanized mice transplanted 
with hematopoietic stem cells (hu-HSC) as recipients for adoptive transfer of infected 
human donor cells. Viral recovery was then measured from transfers of HIV-1 infected 
humanized mouse splenocytes and bone marrow cells infected in vivo and treated with or 
without ART and ART and CRISPR/Cas9. The latter of which resulted in a subset of virus 
sterilized “cured” animals. In each but the “cured” mice replication competent HIV-1 was 
readily detected in all recipient animals. We demonstrate here that adoptive transfer of cells 
between humanized mice is a sensitive assay system to interrogate replication competent 
HIV-1. 
4.2 Introduction 
Antiretroviral therapy (ART) has transformed human immunodeficiency virus type 
one (HIV-1) infection from a life-threatening disease into a life-long chronic condition. 
Though ART maintains viral suppression and preserves immune function it demands strict 
regimen adherence with associated stigmas, costs and inherent drug toxicities. Therefore, 
complete HIV-1 sterilization is the best means to end the epidemic (157). Now after almost 
40 years since the discovery of HIV-1, viral cure has been reported in only two cases (48, 
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116). The major barrier to achieve more wide spread “cure” rests in the ability of HIV-1 to 
sustain latency. Throughout the course of disease and during treatment, a small cell 
population, 1/106 resting CD4+ T cells contains replication-competent dormant HIV-1 
DNA that after activation leads to full blown viral growth (203). While active research 
efforts have pursued elimination strategies for this HIV-1 latent reservoir there are few 
sensitive, precise and practical methods to measure the size, location and distribution of 
such viral compartments (176, 204-206). For the most part viral detection requires viral 
nucleic acid amplification or cell co-cultures (207, 208). While the former readily amplify 
virus, the test fails to differentiate intact from defective provirus (209). In this way it 
commonly overestimates the size of the viral reservoir. Thus, even considering sensitivity 
limitations, cell co-culture assays. based on quantitative viral outgrowth (qVOA) remain 
the gold standard for measures of latent HIV-1 (210). While the qVOA detects < 1% of 
total proviruses induced after activation, additional virus in infectious reservoirs may only 
be awaken by repetitive stimulations (67, 211). Therefore, qVOA underestimate the true 
viral reservoir size.  This has led to the use of animal adoptive transfers for viral recovery. 
Since naturally HIV-1 exclusively infects humans and chimpanzees, immunodeficient 
mice have been used as alternative to recover replication competent virus (43-45, 196, 212) 
and coined as a “mouse viral outgrowth assay (mVOA). The assay was used previously to 
quantify HIV-1 reservoirs from viral suppressed donors (181, 213, 214). After transplant 
with million(s) of human unfractionated peripheral blood mononuclear cells or CD4+ T 
cells, HIV-1 can be successfully recovered. In the current report we employed human 
CD34+ cord blood HSC-reconstituted NOD.Cg-PrkdcscidIL2rgtm1Wjl/SzJ mice as donors for 
adoptive transfer. Interestingly, in donors where animals showed undetectable peripheral 
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viral load (VL), tissue HIV-1 was readily detected. This humanized mouse-to-mouse VOA 
assays demonstrate that adoptive transfer between humanized mice can thus be used to 
interrogate HIV-1 in models of human disease. 
4.3 Materials and Methods 
4.3.1 Generation, HIV-1 infection and treatment of humanized mice 
NSG mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and bred 
under pathogen-free conditions in compliance with ethical guidelines required by the 
National Institutes of Health and the University of Nebraska Medical Center. All 
experimental protocols were approved by the University of Nebraska Medical Center 
Institutional Animal Care and Use Committee. All animal studies were performed 
according to UNMC institutional policies and the National Institutes of Health guidelines. 
Human CD34+ HSCs were enriched from umbilical cord blood using 
immunomagnetic beads according to manufacturer instructions (CD34+ selection kit, 
Miltenyi Biotec Inc., Auburn, CA). Hu-HSC mice were generated by intrahepatic injection 
of human CD34+ HSCs into new-born NSG pups that received 1Gy of irradiation (RS 2000 
X-ray Irradiator, Rad Source Technologies, Buford, GA,) (120, 188). Human cell 
reconstitution was monitored monthly for 5-6 months by flow cytometry (Figure 4.1A) 
(116). At 20 to 24 weeks of age, hu-HSC mice following affirmation of human cell 
reconstitution were intraperitoneally infected with HIV-1NL4-3 (215) or HIV-1ADA (216). 
Both viruses were administered at 104 tissue culture infection dose50 (TCID50)/animal (see 
Table 4.1). Viral infection was confirmed at week 2 by peripheral HIV-1 RNA assays 
(automated COBAS Ampliprep System V2.0/Taqman-48 system, Roche Molecular 
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Diagnostics, Basel, Switzerland) according to the manufacturer’s instructions. Hu-HSC 
mice were then randomly distributed into 4 groups (109). Group 1, HIV-1 infectious 
control; Group 2, HIV-1 and a single intravenous injection of AAV9-CRISPR/Cas9 
(165); Group 3, HIV-1 plus intramuscular administration of dolutegravir (DTG), 
rilpivirine (RPV), lamivudine (3TC), and abacavir (ABC) as a long acting slow effective 
release ART regimen (44, 109, 161, 162) and Group 4, HIV-1 and sequential LASER 
ART and AAV9-CRISPR-Cas9. At 8 weeks after a final CRISPR-Cas9 injection or 9 
weeks after LASER ART ceased (109), donor hu-HSC mice were sacrificed and 
analyzed for immune profiles and viral infection. Splenocytes and bone marrow (BM) 
cells were isolated from donor animals and assessed for cell viability by trypan blue and 
live/dead stains. The TC-20 automated cell counter (Bio-Rad, Hercules, CA) assayed 
viable cells were subsequently resuspended in cold sterile phosphate buffered saline 
(PBS) (GE healthcare life sciences, Logan, UT) then used without delay for adoptive 
transfer.  
4.3.2 Adoptive transfer  
Naïve recipient hu-HSC mice with sustained levels of human cell reconstitution 
were selected for allograft as previously reported (132, 172, 196). Adoptive transfers were 
made by intraperitoneal injection of donor splenocytes or BM cells into recipient animals 
(Table 4.2). To preclude loss of human cell numbers in virus suppressed animals’ mixtures 
of mouse and human cells were isolated together from donor humanized mice. One month 
after engraftment, recipient mice were sacrificed and examined for viral presence. 
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4.3.3 Flow cytometry 
Peripheral blood was collected from facial vein for routine monitoring or cardiac 
puncture at animal sacrifice. Blood was collected in ethylenediaminetetraacetic acid 
(EDTA)-coated tubes and incubated with pan-human monoclonal antibodies to CD45, 
CD3, CD19, CD4, and CD8 (BD Pharmingen, San Diego, CA). Flow cytometry was 
operated on BD LSRII (BD Immunocytometry Systems, Mountain View, CA) system and 
data were analyzed using FlowJo software (BD Pharmingen, San Diego, CA). 
4.3.4 Tissue nucleic acid extraction and viral quantification 
Animal tissues (brain, lung, liver, spleen, BM, gut and kidney) were collected and 
homogenized by Qiagen Tissue Lyser II (QIAGEN, Hilden, Germany). Total cellular 
DNA and RNA were extracted using Qiagen All Prep DNA/RNA Mini Kit (QIAGEN, 
Hilden, Germany). Tissue HIV-1 RNA was reverse transcribed to complementary DNA 
using Thermo-Fisher Scientific Verso cDNA Synthesis Kit (Invitrogen, MA). HIV-1 DNA 
and RNA were quantified by semi-nested real-time PCR as previously described (121). 
HIV-1 DNA isolated from serial dilutions of ACH-2 cell line was adopted as standard 
positive control. The detection limit is below 10 viral copies. Human CD45 
(Hs0036534_g1) and mouse GAPDH (Mm99999915_g1) sequences were applied as 
reference genes from Thermo-Fisher Scientific. 
4.3.5 Immunohistochemistry 
Tissue samples were collected and fixed with 4% paraformaldehyde for 24h then 
processed followed by paraffin embedding. Five-micron thick tissue sections were 
collected and immuno-stained with mouse monoclonal antibodies against human HLA-
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DQ/DP/DR (clone CR3/43, 1:100, DAKO, Carpinteria, CA) and HIV-1 p24 (1:10, DAKO, 
Carpinteria, CA). The polymer-based horse radish peroxidase (HRP) and 3,3′-
Diaminobenzidine (DAB) DAKO EnVision system was used for staining development. 
The nuclei were counterstained with Mayer’s hematoxylin (116). Images were acquired 
with a Nuance EX camera fixed to a Nikon Eclipse E800 microscope using Nuance 
software (Cambridge Research & Instrumentation, Woburn, MA). Human HLA-DR 
images were obtained at 20 x magnifications and HIV-1p24 images were captured at 40 x 
objective magnifications.  
4.3.6 Statistical analyses 
Data were analyzed using GraphPad Prism 8.0 software (La Jolla, CA) and results 
were presented as the means ± the standard error of the mean (SEM).  The Student's t-test 
was used for two-group comparison (two-tailed) while a value of p < 0.05 was considered 
statistically significantly different. Association between 2 parameters was conducted using 
two-tailed Spearman’s rank correlations. 
4.4 Results 
4.4.1 Characterization of donor hu-HSC mice 
Eighteen donor humanized mice were used in this study which included 11 males 
and 7 females (Table 4.1). The median age at the completion of the allograft was 37 (34 to 
45) weeks. Animals with sustained human cell reconstitution had a mean percentage of 
human leukocytes that included CD45+ cells of 25.8% ± 3.7, CD3+ cells of 81.8% ± 2.9, 
CD4+ cells of 58.8% ± 4.5, CD8+ cells of 35.3% ± 4.0 and CD19+ cells at 9.1% ± 2.4 
(Figure 4.1A-B). The mean CD4/CD8 T cell ratios were 2.6 ± 0.7 (Figure 4.1C). No  
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Table 4. 1 Characteristics of Donor Humanized Mice  
Animal ID 
(n=18) 




















3198 M 37 17.9 NL4-3 Dual 181000 
3199 M 37 19.1 NL4-3 Dual 1860000 
3201 F 37 48.0 NL4-3 Dual 44640 
3319 M 36 27.0 ADA Dual TND 
3322 M 36 20.6 ADA Dual 400 
3324 F 34 77.0 ADA Dual TND 
3327 M 39 37.8 ADA Dual 400 








3336 M 34 13.9 ADA Dual TND 
3353 M 34 23.0 ADA Dual 400 
3357 F 34 16.5 ADA / 226000 
3359 F 34 14.2 ADA / 131000 
3636 F 45 14.5 ADA Dual 524000 





Donor hu-HSC mouse ID and sex (F, female; M, male) were listed. Animals were infected with 
either HIV-1NL4-3 or HIV-1ADA, followed with no treatment (/), long acting slow effective release 
antiretroviral therapy (LASER-ART), or LASER-ART plus CRISPR-Cas9 (Dual). Animals were 
sacrificed at 8 weeks after CRISPR-Cas9 injection, which equaled to 9 weeks after last dose of 
LASER-ART, together with untreated animals. Hu-HSC mouse age, peripheral human CD45+ 
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Figure 4. 1 Descriptors of donor humanized mice.  
(A) Flow cytometric gating strategy for human cell reconstitution in NSG-humanized mice. In brief, 
human cells (hCD45+) were gated from total lymphocytes and single cells and subsequently 
grouped into human T lymphocytes (hCD3+) and B lymphocytes (hCD19+). Human CD3+ cells 
were separated into human CD4+ (hCD4+) and CD8+ (hCD8+) T lymphocytes. Detailed immune 
and viral information of individual animal (n = 18) was presented as scatter dots covering (B) 
peripheral human CD45+, CD3+, CD4+, CD8+, and CD19+ cell levels, (C) CD4+/CD8+ T cell 
ratio, (D) plasma viral load (pVL), (E) tissue HIV-1 DNA and (F) tissue HIV-1 RNA distributed 
across spleen, BM, gut, lung, brain, liver, and kidney. Data are expressed as mean ± SEM. Orange 
dots in (D) indicated that pVL was at or below the detection limit of 400 HIV-1 RNA copies/ml. 
Orange dots in (E) and (F) shows tissue viral levels of animals with minimal or undetected pVL. 
The detection limit is below 10 HIV-1 copies as measured using semi-nested real time qPCR using 
HIV specific primers, (G) Spearman’s rank correlation tests were conducted between humanized 
mice pVL and respective spleen DNA (black), spleen RNA (red), BM DNA (blue), and BM RNA 
(green). The Spearman correlation coefficient (r) and p value for each analysis were displayed.  
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significant differences were observed between male and female donors based on the level 
of human cell engraftment and CD4/CD8 T cell ratios (Figure 4.2A-B). The life span of 
human cells in humanized mice supports the feasibility of the small animal model for these 
long-term studies. The mean peripheral viral load of donor humanized mice was 2.5 ± 1.0 
x 105 HIV-1 RNA copies/ml, out of which 3 animals demonstrated virus at and another 3 
animals below the detection limit of detection (Figure 4.1D). Sex did not affect plasma 
viral level (Figure 4.2C). Tissue HIV-1 compartments were readily established in donor 
animals as observed by broad distribution of viral DNA and RNA in spleens, BM, gut-
associated lymphoid tissue, lung, brain, liver and kidney (Figure 4.1E-F). Notably, of 6 
animals that showed plasma viral load at or below the limit of detection only 2 were tissue 
virus negative. The other 4 animals carried low be readily detectable virus, emphasizing 
the essential role of virus in tissues serving as sanctuaries not readily observed in peripheral 
blood. Tissue viral burden did not show significant differences between male and female 
donors (Figure 4.2D-E). To determine the presence of replication-competent virus in 
tissues, single cell suspensions were isolated from spleen and BM, known reservoir sites 
in humanized mice. Recovered cells were then adoptively transferred to naïve reconstituted 
humanized mice to assess levels of viral recovery (Figure 4.3). Correlations between donor 
peripheral viral load and spleen and BM viral burden were recorded (Figure 4.1G). Overall, 
peripheral HIV-1 levels proved to be a viable indicator of tissue viral production. However, 
tissue virus was observed as the most sensitive and specific measure of virus.  
4.4.2 Recipient hu-HSC mice 
A total of 28 naïve humanized-NSG mice were employed as recipients (total 




Figure 4. 2 Descriptions of donor humanized mice.  
Detailed immune and viral profile of individual donor NSG-humanized mice (n = 18) was displayed 
as scatter dots according to sex. Male (n = 11, blue) and female (n = 7, red) donors were compared 
on (A) peripheral human CD45+, CD3+, CD4+, CD8+, and CD19+ cell levels, (B) CD4+/CD8+ T 
cell ratio, (C) plasma viral load (pVL),  (D)  tissue HIV-1 DNA and (E) tissue HIV-1 RNA 
distributed across spleen, BM, gut, lung, brain, liver, and kidney. Data are expressed as mean ± 
SEM. The detection limit (DL) of plasma VL is 400 HIV-1 RNA copies/ml. The detection limit of 





Figure 4. 3 Murine HIV-1 outgrowth assay.   
A mixture of mouse and human cells were isolated from donor NSG-humanized mouse spleen or 
BM and immediately intraperitoneally injected into naïve hu-HSC mice as described in the scheme. 
Recipient animals were maintained for one month before sacrifice and evaluated for HIV-1 
recovery. 
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(spleen recipient, SR) and 10 animals where BM cells were adoptive transferred (BM 
recipient, Figure 4.3 and Table 4.2). The median age of TR at allograft was 30 (25~37) 
weeks with SR at 29.5 (25 to 37) weeks and BR at 30 (29 to 37) weeks. Baseline (pre-
engraftment) humanization of individual TR, SR, and BR was shown in Figure 4.4A-D 
(blue dots) and summarized in Table 4.3. According to sample availability, donor 
splenocytes and BM cells contained a mixture of human- and mouse-originated cells. These 
were extracted and intraperitoneally injected into respective recipient animal. Human cell 
reconstitution levels across the donor tissues were consistent (Figure 4.5). The median 
viable engrafted cell count was 9.6 (5.1 to 19.8) million for SR and 8.7 (4.3 to 10.7) million 
for BR (Table 4.2). Engraftment was well tolerated by all recipient animals. Four weeks 
after adoptive transfer, recipient humanized mice were sacrificed and evaluated for HIV-1 
recovery. Peripheral human CD45+, CD3+ T cells, and CD19+ B cells were not 
significantly changed in TR, SR, and BR before and after engraftment. Peripheral CD4+ T 
cells were significantly decreased in TR, SR, and BR at end point while CD8+ T cells 
significantly increased (Figure 4.4A-C and Table 4.3). CD4/CD8 T cell ratios, as a major 
indicator of immune function and long-term clinical outcomes (217), significantly declined 
in all recipients (Figure 4.4D and Table 4.3). HIV-1 was successfully recovered from the 
majority of allografted humanized mice including those adoptively transferred from donors 
exhibiting minimal infection (# 3322, 3324, 3327, and 3353), but not in the animals 
transplanted from ‘virus-free’ donors (# 3319 and 3336) (Figure 4.4E and Table 4.1 and 
4.2). There were no significant differences between SR and BR plasma VL (Figure 4.4E 
and Table 4.3). Peripheral viral replication was positively correlated with CD4+ T cell loss 
in TR (calculated as pre- minus post-engraftment CD4+ T cell levels) (Figure 4.4F). There  
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3136 3361 F 25 62.8 16.0 455000 / / / / / / 
3181 3355 F 25 37.1 12.3 495000 / / / / / / 
3182 3360 F 25 53.5 14.7 640000 / / / / / / 
3198 3323 M 27 53.3 12.9 966000 / / / / / / 
3199 3347 F 25 61.8 12.0 92200 / / / / / / 
3201 3362 F 25 55.7 19.8 657000 / / / / / / 
3319 3432 F 31 34.3 6.5 TND 3425 F 30 34.9 7.0 TND 
3322 3433 F 31 51.4 9.6 74200 / / / / / / 
3324 3404 M 29 49.7 12.7 50400 3406 F 29 15.2 10.4 508000 
3327 3428 F 33 26.4 5.1 21400 3430 M 33 14.2 10.7 28400 
3328 3354 F 37 15.2 6.1 37200 3351 M 37 15.5 10.0 4460 
3333 3422 F 30 24.3 9.0 19200 3407 F 30 27.2 5.2 34800 
3336 3434 F 31 47 6.5 TND 3388 F 34 18.6 6.0 TND 
3353 3435 F 31 25.4 9.0 159000 3416 M 30 39.8 4.3 42400 
3357 3409 F 31 24.1 9.5 552000 / / / / / / 
3359 3410 F 31 9.33 9.6 53400 3411 F 31 28.6 8.3 64800 
3636 3912 M 29 30.9 8.9 590000 3913 M 29 35.4 9.8 466000 








The ID of individual recipient hu-HSC mouse and corresponding donor hu-HSC mouse 
was listed. According to sample availability, a total of 18 hu-HSC mice received splenocytes 
transplant and 10 hu-HSC mice acquired BM transplant. Sex (F, female; M, male), age, and 
peripheral human CD45+ (hCD45+) cell levels of recipient animals before adoptive transfer (AT) 
were summarized. A range of 4.3~19.8 million live cells were engrafted. Recipient hu-HSC mice 
were maintained for 4 weeks before sacrifice and end point plasma HIV-1 RNA counts were 
displayed. TND, target not detected. 
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Figure 4. 4 Descriptors of recipient humanized mice.  
Peripheral human cell levels (hCD45+, hCD3+, hCD4+, hCD8+, and hCD19+ cells) before (blue) 
and after (red) adoptive transfer were depicted for (A) total recipient (TR) humanized mice, and 
subgroups (C) spleen recipient (SR) and (D) bone marrow recipient (BR) humanized mice. (B) 
Scatter plots represented CD4+/CD8+ T cell ratio of individual TR, SR, and BR before (blue) and 
after (red) adoptive transfer. (E) Plasma viral load (pVL) of individual recipient humanized mouse 
at sacrifice was displayed for TR (black), SR (blue), and BR (red). Orange dots represented 
humanized mice receiving engraftment from donors with minimal or undetected plasma VL. The 
detection limit is < 400 HIV-1 RNA copies/ml. A Spearman’s rank correlation test was conducted 
to investigate the association (F) between recipient humanized mouse plasma VL and respective 
peripheral CD4+ T cell loss and (G) between recipient humanized mouse plasma VL and respective 
end-point peripheral CD4+/CD8+ T cell ratio. The Spearman correlation coefficient (r) and p value 
for each analysis were displayed. In A-E, data are expressed as mean ± SEM and considered *, *** 




Table 4. 3 Peripheral human cell reconstitution and plasma viral load of recipient 
humanized mice 
 
TR (n = 28) SR (n = 18) BR (n = 10) 
Pre Post Pre Post Pre Post 
Peripheral 
human cells (%) 
CD45 34.4 ± 2.9 34.8 ± 3.1 38.4 ± 3.9 39.1 ± 3.9 27.1 ± 3.4 26.9 ± 4.0 
CD3 58.5 ± 4.7 67.5 ± 3.5 62.7 ± 5.9 69.9 ± 4.2 51.0 ± 7.8 63.2 ± 6.4 
CD4 70.4 ± 1.7 45.8 ± 4.1 71.4 ± 1.7 40.0 ± 5.6 68.5 ± 3.8 56.2 ± 3.7 
CD8 25.6 ± 1.5 47.0 ± 3.7 24.9 ± 1.6 52.2 ± 5.1 26.8 ± 3.4 37.6 ± 3.1 
CD19 33.3 ± 4.6 23.1 ± 3.2 28.8 ± 5.9 20.7 ± 3.9 41.2 ± 7.3 27.5 ± 5.7 
CD4/CD8 3.2 ± 0.3 1.4 ± 0.2 3.2 ± 0.3 1.3 ± 0.4 3.3 ± 0.7 1.7 ± 0.2 
Plasma HIV-1 RNA  
(x105 copies/ml) 
/ 2.3 ± 0.5 / 2.8 ± 0.7 / 1.3 ± 0.6 
 
TR, total recipient; SR, spleen recipient; BR, bone marrow recipient; Pre, pre-adoptive transfer; 





Figure 4. 5 Human cell reconstitution in donor humanized mouse spleens and BM.  
Total DNA was isolated from donor spleen (blue) and BM (red) and subjected to real-time 
quantitative PCR analysis. Human CD45 was employed as human cell marker and mouse GAPDH 
as reference gene. Comparative ΔΔCT method was used. Data were shown as the median of fold 
change of individual human CD45/mouse GAPDH expression. 
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was a negative association between TR plasma VL and end point CD4/CD8+ T cell ratio 
(Figure 4.4G). We observed a positive correlation of plasma VL between donor and SR 
but not between donor and BR (Figure 4.6). Tissue HIV-1 infection as measured to look 
for viral DNA (Fig. 4.7A and C) and RNA (Fig. 4.7B and D) was readily established and 
disseminated amongst spleens, BM, guts, lungs, brains, livers, and kidneys in allografted 
humanized mice except those 4 animals obtaining engraftment from donors 3319 and 3336 
(Figure 4.7A-D). We observed a positive correlation between the donor tissue proviral 
DNA amplification with that of recipient tissue nucleic acid amplification. There were not 
significant differences on tissue viral burdens (except gut-associated lymphoid tissue HIV-
1 DNA) between SR and BR (Figure 4.7A-D). Tissue viral infection in recipients 
wasconfirmed by immunohistochemitry (Figure 4.8). Spleen and lymph node samples 
from SR and BR were stained for human HLA-DR and HIV-1p24 at the same region. 
Human HLA-DR signal (shown as brown dots) was readily detected in all recipients 
indicating proper humanization of the animals. While not being observed in recipients 
engrafted from sterilized donors 3319 and 3336 (data not shown), HIV-1p24 (shown as 
brown dots) was detected in both SR (Figure 4.8A) and BR (Figure 4.8B) that received 
engraftment from donors with undetectable or close-to-detection limit plasma VL. Viral 
replication was more prominent in lymph node than spleen from the same animal. 
Altogether, these data emphasize that replication-competent HIV-1 persists in tissue 
sanctuaries even under effective ART. 
4.5 Discussion 





Figure 4. 6 Correlations between donor and recipient mouse plasma VL.  
Spearman’s rank correlation tests were conducted to investigate associations between donor 
humanized mouse plasma VL and respective SR plasma VL (blue) and respective BR plasma VL 
(red). The Spearman correlation coefficient (r) and p value for each analysis were displayed. The 




Figure 4. 7 Tissue HIV-1 DNA and RNA in recipient humanized mice.  
(A) Tissue HIV-1 DNA and (B) tissue HIV-1 RNA in total recipient (TR) were established in 
spleen, BM, gut, lung, brain, liver, and kidney. (C) Tissue HIV-1 DNA and (D) tissue HIV-1 RNA 
in subgroups spleen recipient (SR) (blue) and bone marrow recipient (BR) (red) were displayed. 
The detection limit is below 10 HIV-1 copies as measured by real-time semi-nested qPCR assays. 







Figure 4. 8 Detection of HIV-1p24 in recipient humanized mouse tissues.  
A representative photomicrographic analysis of spleen and lymph node samples from spleen and 
BM recipient humanized mice tissues adoptively transferred from either undetectable or close to 
detection limit (400 copies of HIV-1 RNA/ml) plasma viral load of donor mice. Spleen and lymph 
node tissues were collected from (A) Spleen recipient and (B) BM recipient mice at necropsy with 
formalin fixed and paraffin embedded for nest step. Five M thick sections were cut and then 
stained with antibodies specific for human HLA-DR and HIV-1p24. Representative images from 
each group were selected and pictures were captured for both (shown as brown dots) from 
individual animals. The recipient mice numbers are presented on the left panel. The plasma viral 
load of the donor mice used for adoptive transfer of cells are presented on the top of each mice 
rows, suggesting the sensitivity of the method we adopted to detect tissue viral reservoirs when the 




nonproductive infection that is termed viral latency. Elucidation of locale and extent of this 
viral reservoir is imperative if viral elimination is to be achieved. Current methods to 
quantitate latent HIV-1 infection relies principally on the use of nucleic acid polymerase 
chain reaction (PCR) and qVOA-based assays. While both are sensitive and specific both 
fall short in reflecting the absolute viral reservoir as it exists at extremely low levels (218, 
219). The lack of assay sensitivity was seen from allogeneic hematopoietic stem cell 
transplant (HSCT) recipients who were found to be HIV-1 negative by conventional PCR 
and qVOA by tests of peripheral blood and rectal tissue biopsy for time periods of up to 
years before ART interruption (ATI). Unfortunately, both patients experienced viral 
resurgence (220). In the case of the “Mississippi baby”, ART was initiated 30 hours after 
birth and while the baby remained virus free by PCR and qVOA tests before and after ATI 
virus rebounded after 27 months (50). From these studies it is argued that, ATI is the 
ultimate standard to justify HIV-1 cure. Both above cases emphasize that more sensitive 
assays are urgently required at the age of pursuing HIV-1 eradication. However, to date, 
studies that involved thousands of individuals undergoing ATI, only 2 cases were 
considered free of HIV-1 infection while others unexclusively experienced viral rebound 
(47, 48, 221). ATI endowed patients with unnecessary risks can be avoided if more 
sensitive assays for latency evaluation are developed.  
An ideal model should have a shortened disease course for completion of 
therapeutic testing in a limited time and should possess immune cell markers that are 
readily translatable to humans. That encouraged the creation of immunodeficient rodents 
that accommodate human xenografts permitting study of diseases exclusively in human 
such as HIV-1. Mouse models have extended our understanding and prepared us with the 
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therapy for this once life-threatening disease. From the past 5 years, researchers employed 
these models to develop an in vivo VOA by engrafting blood samples from HIV-1 infected 
patient into either non-humanized or humanized mice (222). HIV-1 was successfully 
recovered from animals that received transplant from viral suppressed donors. In general, 
humanized mice are more sensitive on viral recovery than regular immunodeficient mice. 
There is a direct relationship between reservoir size and time to reawake. More importantly, 
mVOA was able to capture latent reservoirs that were not detected by qVOA (181, 213) 
revealing its better sensitivity on reservoir measurement.  
Additionally, due to limited access of patient tissues, clinical determination of viral 
reservoirs, including mVOA, mostly relies on peripheral blood test while majority of latent 
cells hide in variant tissues (223). Humanized mice can overcome these challenges by 
enabling analysis of individual tissue types. The superior sensitivity of mVOA over qVOA 
likely attributes to a combination of factors including a physiological environment that 
favors the expansion and survival of donor cells, abundant HIV-1 susceptible cells (as in 
humanized mice) facilitating viral spread, and graft-versus-host (GvH) reaction that 
promotes the reversal of latent infected cells. 
Currently, humanized mice VOA has been rarely studied due to lack of HIV-1 
elimination strategies. In addition, finding viral sanctuaries from human tissues remains 
challenging, humanized mice can provide an alternative pathway for engrafting individual 
mouse tissues into naïve recipients to monitor viral resurgence. Recently our lab developed 
a combinatorial LASER ART and CRISPR/Cas9 strategy to pursue HIV-1 cure (109). 
After an 8 to 10 weeks period absence of ART, donor splenocytes and BM cells were 
adoptively transferred to naïve humanized mice. To maximally recover any replication 
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competent donor remaining virus, we adoptively transferred the maximum number of cells 
according to sample availability. Engraftment was well tolerated in all the recipients that 
were further kept for one month before sacrifice, which is generally sufficient for HIV-1 
reservoirs to relapse (181, 213, 214). Animals receiving engraftment from the donors with 
higher plasma viremia (12/18) before allograft exhibited rigorous HIV-1 replication, 
indicating that similar to human samples, viral outgrowth from humanized mice-derived 
cells was permissive. In four animals (# 3322, 3324, 3327, and 3353), where peripheral VL 
was extremely low or undetected, condition similar to clinically viral suppressed patients, 
HIV-1 was detected in a broad range of tissue types, as observed in autopsy specimens of 
treated patients (35). Virus from these 4 animal tissues was successfully recovered from 
engrafted humanized mice, demonstrating that these viruses were latent and replication-
competent. This may explain the failure of viral control in patients who received long-term 
suppressive treatment and went through ATI (55, 57). On the other hand, when virus is 
eliminated from all the sanctuaries it could not be recovered even after adoptive transfer (# 
3319 and # 3336).  
Viral amplification levels in the donors are not associated with that of recipients as 
previously observed (213), which can be attributed to multiple factors including donor viral 
burden, numbers of adoptively transferred cells, and recipient environment. One drawback 
in the present study is lack of comparison on detection sensitivity between qVOA and 
mVOA due to sample insufficiency and will be pursued in the future. We posit MVOA 
should be conducted only after repetitive qVOA presenting negative to reduce animal 
numbers. Sufficient number of cells should be engrafted to prevent false negative result. 
MVOA is not always viable when HIV-1 reservoir size is extremely small. For example, 
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in a recent report, patient A who initiated ART 10 days after infection remained viral 
negative (by PCR and qVOA) by extensive scrutinization from blood, colorectum, lymph 
node, cerebral spinal fluid, and BM for 2 years. More than 500 million CD4+ T cells were 
isolated and engrafted into 10 NSG mice (53 million per mouse) but only one mouse 
displayed minimal viremia (201 copies/ml). The patient underwent ATI and maintained 
HIV-1 remission for 7.4 months before viral rebound. An estimated reservoir size of 200 
cells resided, before ATI, which might be missed even after 1 billion CD4+ T cells were 
scrutinized (96), resulting in rebound. 
In summary, this study describes an hu-HSC mouse-based MVOA that successfully 
recovered virus from donor infected humanized mouse tissues. Notably these animals 
possessed either detectable or undetectable plasma VL. This observation emphasizes the 
‘untouchable’ tissue HIV-1 reservoirs as a major obstacle to viral cure even under highly 
suppressive ART (154). Sensitivity of mVOA can be improved by using humanized instead 
of non-humanized NSG mice, in vitro stimulation (e.g. anti CD3/CD28 antibodies or 
latency reversing agents) before transplant, and in vivo CD8+ T cells depletion after 
engraftment (222). In addition, mVOA can be successfully employed to interrogate HIV-
1 latency from individual tissue or cell type of interest. Future work needs to be conducted 




Chapter 5 Conclusions and Future Directions 
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Since the first case of HIV/AIDS identified in 1981, this malicious disease has led 
to a total of 74.9 million infections and 32 million death by 2018 according to UNAIDS. 
Development of highly active antiretroviral therapy (HAART) successfully halts viral 
spread and renders patients a nearly normal life. An HIV-1 cure has been pursued for the 
past decade while only realized in two patients who received aggressive procedures (47, 
48). The major barrier to HIV-1 eradication rests on latent viral reservoirs containing 
replication-competent HIV-1 DNA that is resistant to current therapies including HAART, 
latency reversing agents (LRAs), broadly neutralizing antibodies (bnAbs), and immune 
therapy. While HIV-1 replication is efficiently inhibited under HAART, viral sequences 
integrated into host genome remain untouchable and resume viral production after 
treatment is discontinued. Therefore, HIV-1 eradication is only possible when genomic 
viral DNA is edited. The development of CRISPR-Cas9 system eases the design and 
improves the specificity and sensitivity of gene editing, making it possible for broad 
application on human genetic diseases including leukemia, blindness, cystic fibrosis, 
muscular dystrophy, and others (106, 224). While CRISPR-Cas9 designed to target specific 
HIV-1 sequences has successfully excised viral genomes in cellular and small animal 
model, it remains unclear if CRISPR-Cas9 can synergize with other treatments to achieve 
a complete HIV-1 eradication (165, 166). Because HIV-1 is a human-specific disease, we 
first developed a human CD34+ hematopoietic stem cells (HSCs)-reconstituted humanized 
mouse model that simulates human immune system susceptible to HIV-1 infection (43, 
120). Next HIV-1 temporal and spatial dynamics during acute infection of humanized mice 
were identified to guide the follow-up design of HAART intervention (196). We observed 
early HIV-1 tissue compartments in animal spleen, lung, and liver by 3 days post-infection 
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and broad viral distribution by 14 days post-infection at which point HAART was 
determined to initiate in the following study (109). To maximize viral restriction in the 
setting of optimal gene-editing efficiency by CRISPR-Cas9, a combination of 
nanoformulated prodrugs (RPV, MDTG, MABC, and M3TC) were developed (namely 
LASER ART) characterized with prolonged half-life and enhanced tissue penetration (44, 
45, 161, 162). Through this combinational strategy applying sequential administration of 
LASER ART and CRISPR Cas9, for the first time a complete HIV-1 cure was achieved in 
a subset of infected humanized mice which was demonstrated in three independent 
experiments (109). This success is attributed to a combination of factors including a 
suitable animal model, control of viral set points, early treatment intervention, potent 
LASER ART reaching viral reservoirs, and the widespread employment of CRISPR-Cas9 
gene editing. To this end, these proof-of-concept results offer novel and realistic pathways 
toward HIV-1 elimination. 
To increase the “HIV-1 cure” rate, we will first reinforce the efficacy of two 
components (LASER ART and CRISPR-Cas9) in the strategy. The potency of LASER 
ART partially lies on the lipophilic and hydrophobic properties which can be improved 
with chemical modification. Taking cabotegravir (CAB) as example, through adjusting 
various fatty acid chains, a new prodrug linking 18-carbon stearic acid onto parent CAB 
has shown enhanced half-life and tissue penetration compared to the first-generation 
prodrug myristoylated CAB (MCAB) (unpublished data). Alternative pathway to improve 
the efficiency of LASER ART is to direct treatment to targets through specific ligand 
binding. Folate acid (FA) receptors are highly expressed on activated macrophages which 
are the primary sites of HIV-1 infection (225). Previous studies from our group have shown 
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that FA-coated nanoART is superior to non-FA-coated nanoART as to extended drug half-
life, higher drug concentrations, and better HIV-1 inhibition (198, 226). Whether or not 
this targeting strategy can boost the competence of current prodrugs needs further 
investigation. To improve genomic excision of HIV-1, a more efficient delivery system of 
CRISPR-Cas9 can be pursued. Adenovirus has been widely applied as a gene delivery 
vector (227). The highly effective transfection of adenovirus is attributed to a broad 
expression of adenovirus receptor on human cells (228). However, this also limits its 
specificity when it is used to deliver gene therapy to HIV-1 containing cells which are 
primarily CD4+ T cells and monocytes/macrophages and may cause unnecessary off-target 
events. To address this issue, the virus-like particles (VLPs) that possess HIV-1 envelop 
protein for specific CD4 binding but fail to induce infection or replication due to gene 
modification have been under development as novel vector for CRISPR-Cas9. Employing 
multiple guide RNAs that target different HIV-1 and/or host sequences may also enhance 
viral suppression and elimination as shown in Figure 3.14. While CRISPR-Cas9 is 
powerful in gene editing and may lead to an HIV-1 cure, researchers should always be 
precautious about the potential off-target effects caused by gene manipulation in general 
(229). Although in our humanized mouse study, no off-target effects were detected in 
CRISPR-Cas9 treated animals after careful scrutinization, avoiding any potential off-target 
effects when designing gene therapy and performing post-procedure assessment should be 
required. The mechanisms of HIV-1 persistence are complicated. To maximize viral 
restriction and elimination of HIV-1 latency, one or multiple therapies can be employed 
such as LRAs, bnAbs, immune checkpoint inhibitors, CAR-T cells, etc. Lastly, observation 
in small animal models cannot fully predict the outcomes in human beings. Our 
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combinational strategy of HIV-1 eradication need to be readjusted and tested in larger 
animals such as non-human primates and eventually in human patients. To this end, we 
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